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ABSTRACT

TOLL- LIKE RECEPTOR 4 MUTATION SUPPRESSES
HYPERHOMOCYSTEINEMIA- MEDIATED HYPERTENSION

Anastasia Familtseva
June 1, 2016
Background: Hyperhomocysteinemia (HHcy) has been observed to promote
hypertension, but the mechanisms are unclear. Toll-like receptor 4 (TLR-4) is a
cellular membrane protein that is ubiquitously expressed in all cell types of the
vasculature. TLR-4 activation has been shown to promote inflammation that has
been associated with pathogenesis of hypertension. In this study, we
hypothesize that HHcy induces hypertension by TLR-4 activation that promotes
inflammatory cytokine up-regulation (IL-1β, IL-6, TNF-α) and initiation of
mitochondrial dysfunction leading to cell death and chronic vascular
inflammation.
Methods: To test this hypothesis, we used C57BL/6J mice (WT); Cystathionineβ-synthase deficient mice (CBS+/-) with genetic mild HHcy; C3H/HeJ (C3H)
vi

mice, with TLR-4 mutation and mice with combined genetic CBS enzyme
deficiency and TLR-4 mutation (CBS+/-/C3H). Arterial blood pressure was
measured using non- invasive tail- cuff method. Ultrasonography of the superior
mesenteric artery was performed to assess resistance to blood flow and to
measure wall/lumen ratio. Collagen deposition in the SMA was analyzed using
Masson’s trichrome staining. The levels of oxidative stress markers and
endothelial nitric oxide synthase (eNOS) were measured by western blotting and
the expression of endothelial cell markers analyzed by immunohistochemistry
(IHC). The proteins of mitochondrial dynamics were assessed by western blot,
qPCR and IHC. The levels of inflammatory markers were analyzed by qPCR and
IHC. Mitochondrial apoptosis protein expression was measured by western blot,
qPCR and IHC. DNA fragmentation in the SMA was assessed by TUNEL assay.
Results: Ultrasonography of the SMA detected an increase of wall-to-lumen ratio
and resistance to blood flow in CBS+/- mice that was associated with arterial
blood pressure elevation in the same mouse model detected by tail- cuff
measurement. The SMA from CBS+/- mice expressed elevated markers of
inflammation, oxidative stress, mitochondrial fission and mitochondrial apoptosis.
The increased collagen accumulation was observed in the SMA of CBS+/mouse model. However, all these changes were attenuated in CBS+/-/C3H
mouse model.
Conclusions: We conclude that HHcy promotes TLR-4- driven chronic vascular
inflammation and mitochondria- mediated cell death inducing peripheral vascular
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remodeling and hypertension. TLR-4 mutation attenuates vascular inflammation
and cell death that prevents vascular remodeling and suppresses hypertension.

viii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS……………………………………………………………...iv
ABSTRACT……………………………………………………………………………...vi
LIST OF FIGURES……………………………………………………………………..xi
CHAPTER I: INTRODUCTION………………………………………………………...1
CHAPTER II: BACKGROUND…………………………………………………………4
Superior mesenteric artery……………………………………………………………..4
Peripheral vascular remodeling and hypertension…………………………………..6
Homocysteine………………………………………………………………………….11
Hyperhomocysteinemia……………………………………………………………….14
Hyperhomocysteinemia and inflammation………………………………………….17
Hyperhomocysteinemia and mitochondrial dysfunction…………………………...26
CHAPTER III: HYPOTHESIS AND SPECIFIC AIMS……………………………...34
CHAPTER IV: MITOCHONDRIAL FRAGMENTATION FACILITATES
MESENTERIC ARTERY REMODELING IN HYPERHOMOCYSTEINEMIA……37

ix

CHAPTER V: TOLL- LIKE RECEPTOR 4 MUTATION SUPPRESSESS
HYPERHOMOCYSTEINEMIA- INDUCED HYPERTENSION……………………61
CHAPTER VI: SUMMARY, CONCLUSION AND FUTURE DIRECTIONS
REFERENCES…………………………………………………………………………90
CURRICULUM VITA…………………………………………………………………120

x

LIST OF FIGURES
FIGURE

PAGE

1. Schematic representation of homocysteine metabolism…………………..13
2. Schematic representation of overall hypothesis……………………………36
3. Genotyping of WT, CBS+/-, C3H and CBS+/-/C3H mice………………….49
4. Western blotting for cystathionine β- synthase enzyme…………………...50
5. Hyperhomocysteinemia up regulates ROS…………………………………51
6. Western Blotting for mitochondrial fission and fusion proteins……..........52
7. qPCR for mitochondrial fission and fusion gene expression……………...53
8. Immunohistochemistry for mitochondrial fission and fusion proteins…….54
9. Immunohistochemistry for CD31 and connexin 40 proteins………………55
10. Western blotting for eNOS protein expression…………………………….56
11. Masson’s trichrome staining…………………………………………………57
12. Blood pressure measurement……………………………………………….74
13. Ultrasonography (wall/lumen ratio)………………………………………….75
14. Ultrasonography (resistive and pulsatility indexes)………………………...76
15. Immunohistochemistry for TLR- 4 and TNF- α……………………………..77
16. qPCR for inflammatory markers: IL- 1β, IL- 6……………………………...78
17. qPCR for BAX gene expression……………………………………………...79
18. Western blotting for caspase- 9 protein expression……………………….80
xi

19. Immunohistochemistry for cleaved caspase- 3……………………………81
20. TUNEL assay………………………………………………………………….82

xii

CHAPTER I
INTRODUCTION
Homocysteine (Hcy) is a non-protein-coding α-amino acid that is
synthesized from dietary protein-derived methionine. The excess of Hcy in
plasma is cleared via two essential pathways remethylation and transsulfuration
pathways [1]. In remethylation, cobalamin-dependent methionine synthase (MS)
and cobalamin-independent betaine-homocysteine methyltransferase (BHMT)
enzymes are used to convert Hcy back to methionine [2]. In transsulfuration that
occurs only in the small intestine, liver, pancreas and kidney a cofactor- vitamin
B6 is required to convert Hcy to cystathionine by cystathionine β- synthase (CBS)
and cystathionine to cysteine by cystathionine gamma-lyase (CSE) [3]. Cysteine
is further utilized as a precursor for synthesis of antioxidant glutathione or
vasodilator hydrogen sulfide. Mutations in MTHFR, CBS and CSE enzymes and
nutritional deficiencies in vitamin cofactors (B12, B9, and B6) are the common
causes of HHcy. The “normal” range for plasma tHcy is about 5-15 uM/L and
hyperhomocysteinemia (HHcy) is defined as an elevation of plasma tHcy level
above 15uM/L that is classified on moderate (16-30 uM/L), intermediate (31-100
uM/L) and severe (more that 100 uM/L) HHcy [4]. Epidemiological studies have
described HHcy as an independent risk factor of atherothrombotic vascular
disease complications of which include stroke, myocardial infarction, peripheral
1

vascular disease, miscarriage, pulmonary embolism and coronary heart disease
[5, 6]. A significant amount of other studies have shown a positive correlation
between Hcy plasma levels and hypertension [7, 8]. It has been implicated that
the possible mechanisms that are involved in HHcy-mediated hypertension could
be reactive oxygen species-induced vascular endothelium damage that causes
impairment in vasodilation, vascular remodeling with elastin degradation and
collagen deposition and facilitation of vascular inflammation [6, 9]. Several in vitro
studies have shown inflammatory markers up-regulation in HHcy, including
activation of NF-kB that is inflammatory cytokine transcription factor [10]. Zhang
et al. have reported that circulating pro-inflammatory cytokine levels (IL-6, TNF-α
and MCP-1) are positively correlated with Hcy serum levels [11]. Scherer et al.,
have also observed mild HHcy-mediated augmentation of inflammatory cytokine
production (IL- 1β, IL- 6, TNF- α, MCP-1) in serum and different organs [12].
Although HHcy is known to promote downstream pro- inflammatory cytokine
elevation, the precise mechanism of triggered inflammatory response is not
clearly defined until now. Pathogen recognition receptor, and in particular Tolllike receptor 4 (TLR-4) is a foreign antigen sensor that plays role in innate
immune system activation and has recently gained a significant attention in the
field of hypertension. TLR- 4 is ubiquitously present within the vasculature
(endothelial cells, VSMC) and its activation promotes inflammatory cytokine upregulation facilitating vascular inflammation that is the hallmark of hypertension
[13, 14].
Mitochondrial dysfunction and mitochondria-dependent apoptosis have
2

been shown to promote endothelial cell loss leading to endothelial dysfunction
[15, 16] that contributes to pathogenesis of hypertension [17, 18]. Impaired
mitochondrial dynamics such as excessive mitochondrial fission and decreased
mitochondrial fusion is associated with cardiovascular diseases and diabetes [1922]. Studies have implicated that HHcy facilitates excessive mitochondrial fission
[23] and mitochondria-mediated cell death [24] however, the mechanisms are not
well described. In the current study, we aimed to explore whether HHcy activates
TLR-4 with downstream pro- inflammatory cytokine elevation that facilitates
vascular inflammation. These events subsequently induce mitochondrial
dysfunction characterized by excessive mitochondrial fission and mitochondrial
apoptosis contributing to vascular remodeling followed by hypertension. In
addition, we elucidated the role of TLR-4 mutation in attenuation of HHcymediated vascular inflammation and mitochondria- dependent cell death that
suppresses hypertension.
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CHAPTER II
BACKGROUND

Superior Mesenteric Artery
Anatomy and Physiology of the Superior Mesenteric Artery
Superior mesenteric artery is one of the branches of abdominal aorta
(inferior phrenic, celiac, superior mesenteric, middle suprarenal, renal, gonadal,
lumbar, inferior mesenteric, median sacral, common iliac arteries) that arises
usually at the level of L1, 1-1.5 cm below celiac artery and is just superior to the
origin of the renal arteries [25]. The SMA supplies blood to the pancreas, lower
part of the duodenum, jejunum, ileum, ascending colon and transverse colon,
giving respective branches: inferior pancreaticoduodenal artery, jejunal arteries
(usually 4-6 arteries), ileal arteries (usually 8-12 arteries), ileocolic artery, right
colic artery and middle colic artery [25, 26]. Splanchnic blood flow at rest is about
25% of cardiac output, but can fluctuate between 10% -35% of cardiac output
depending upon magnitude, time and composition of food ingestion. The mean
blood flow in human celiac axis and SMA varies from 300- 1200 mL/min [27]. At
rest, mesenteric flow has intermediate to high resistance with low diastolic flow.
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With food ingestion, mesenteric vascular bed is maximally dilated with low
resistance to blood flow. Mesenteric blood flow is controlled by extrinsic and
intrinsic systems [25]. Extrinsic system regulates splanchnic blood flow through
neural and hormonal axis. Mesenteric circulation is predominantly controlled by
sympathetic nervous system through activation of α1- adrenoreceptors that are
highly expressed in the intestinal vasculature. Hence, a significant reduction in
intestinal blood flow is mediated by increased sympathetic nerve activity during
strenuous exercise or pathologically low arterial blood pressure. Mesenteric
vascular bed also contains β- adrenoreceptors that are less prevalent than αreceptors. Stimulation of β- adrenoreceptors with isoproterenol produces
vasodilation of the mesenteric vasculature. Apart from neural regulation,
mesenteric blood flow is controlled by hormonal systems. The loss of
extracellular volume stimulates renin- angiotensin axis, inducing mesenteric
vascular bed vasoconstriction through the direct effect of angiotensin II as well as
indirectly through adrenergic receptors [28]. In addition, the decrease in blood
volume and hyperosmolarity stimulate vasopressin release that produces
profound mesenteric vasoconstriction and venorelaxation. The intrinsic system
includes myogenic and metabolic control mechanisms of the circulation [29].
Adenosine is one of the metabolites that plays role in mesenteric vasodilation by
increasing intestinal perfusion. Local release of nitric oxide induces vascular
smooth muscle cell relaxation, leading to vasodilation that helps to preserve
sufficient intestinal perfusion compensating for systemic hypotension. The
intrinsic system is poorly developed in the intestinal circulation and hence,
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extrinsic mechanism is a predominant regulator.
SMA wall comprised of three layers: tunica intima, tunica media and tunica
adventitia [30]. The most inner layer of the vascular wall is tunica intima that
includes a single alignment of endothelial cells. The next layer of the arterial wall
is tunica media that is comprised of vascular smooth muscle cells with some
elastin and collagen and separated from tunica intima by internal elastic
membrane. Tunica media of the SMA has well defined circular layer of smooth
muscle cells that classifies this artery as muscular artery, allowing contraction or
relaxation to redistribute splanchnic blood flow if needed. The most outward layer
of the arterial wall is tunica adventitia that consists of collagen and elastin and is
separated from tunica media by poorly defined external elastic membrane.

Peripheral Vascular Remodeling and Hypertension
Peripheral Vascular Remodeling. Classification.
Arterial remodeling is the form of vessel wall adaptation to mechanical and
hemodynamic stimuli, characterized by structural and functional changes of the
vascular wall mediated by different mechanisms (hyperplasia of the arterial
intima and media, redistribution of extracellular matrix components such as
collagen and elastin, fibrosis, arterial calcification and endothelial dysfunction).
Structural reorganization of the vascular wall architecture facilitates elevation of
resistance to blood flow, contributing to amplification of total peripheral resistance

6

that is the hallmark of hypertension [31]. Arterial remodeling is classified based
on changes in luminal diameter: outward remodeling (increased vessel diameter)
and inward remodeling (decreased vessel diameter), and based on changes in
wall thickness: hypertrophic (thickening of the vessel wall), eutrophic (constant
wall thickness) and hypotrophic (thinning of the vascular wall) [32]. Outward
hypertrophic remodeling is characterized by increased vessel diameter and
thickening of intimal and medial layers of the vascular wall promoting stiffness of
the large central elastic arteries that occurs in hypertension [31]. However,
muscular peripheral arteries develop one of two types of arterial remodeling:
inward eutrophic or inward hypertrophic remodeling. In the first type of
remodeling, that is attributed to essential hypertension in humans and is also
found in spontaneously hypertensive rat model, the lumen is reduced and the
wall thickness is constant and similar to that of normotensive individuals [31]. The
second type or inward hypertrophic remodeling is developed in secondary
hypertension (renovascular hypertension, pheochromocytoma, diabetic, saltdependent and mineralocorticoid hypertension) and is characterized by reduced
lumen and enlarged media cross-sectional area [31].
Pathogenesis of Arterial Remodeling
Arterial remodeling occurs due to the complex of mechanisms (smooth muscle
cell proliferation and differentiation, elastin degradation and collagen deposition,
arterial calcification and endothelial dysfunction) that mediate reorganization of
all layers of the vascular wall [32]. Tunica media that is comprised of smooth
muscle cells (SMC) plays a major role in regulation of vascular tone and diameter
7

through smooth muscle contraction and relaxation. SMC content in the tunica
media raises up to 85% with decrease in vessel diameter. In contrast to large
central elastic arteries, SMC of the small arteries circumferentially arranged with
a pitch angle smaller than 20. Such an arrangement of SMC allows optimal
resistance against vessel distention [33]. Under normal condition, SMC have
contractile phenotype and express respective SMC proteins: smooth muscle 22alpha (SM22α), alpha- smooth muscle actin (αSMa) and smoothelin [34, 35].
However, studies have shown that in vascular injury or stress contractile SMC
undergo phenotype switching, where SMC differentiate into synthetic phenotype
that further gives two classes of SMC (migratory- proliferative or osteogenic
phenotypes) [32]. Inflammation, oxidative stress, mechanical stretch, angiotensin
II, transforming growth factor-β (TGF-β), matrix metalloproteinases (MMPs) are
the major stimuli for vascular smooth muscle cells (VSMC) phenotype switching.
Synthetic VSMC secrete MMPs allowing the migration of SMC into intima by
detaching cells from the basement membrane and extracellular matrix (ECM)
[36]. The migrated SMC are involved in proliferation and hyperplasia of intima
promoting thickening of the arterial wall. High extracellular levels of calcium and
phosphate and the absence of inhibitors of calcification allow VSMC
differentiation into osteogenic phenotype, where VSMC have the features
attributed to osteoblasts or chondrocytes [37]. Osteogenic phenotype decreases
the expression of SMC markers and induces intense calcification of elastic fibers
in vascular wall.
The next event that contributes to arterial vascular remodeling is
8

redistribution of ECM proteins in the vascular wall. ECM occupies more than half
of the vascular wall mass and contains elastin, collagen, fibronectin, fibrillins,
proteoglycans and leucine- rich glycoproteins [38]. ECM maintains vascular
function under normal and pathophysiological conditions. Interaction of vascular
wall cells with ECM regulates cell migration, adhesion, proliferation and
phenotype. Integrins are the ECM receptors that are engaged by cells to sense
the ECM content change that is involved in tissue remodeling.
Elastin is mainly synthesized by SMC, however endothelial cells and
adventitial fibroblasts are able to produce tropoelastin. Large resistance arteries
contain internal and external elastic membranes and some elastic fibers located
between smooth muscle cell fibers. In contrast to large elastic arteries, elastin of
small arteries and arterioles is only limited to internal elastic membrane. Large
central elastic arteries contain significant amount of elastin (111mg/g in the rat
carotid artery) assisting in mitigation of pressure pulsations. The amount of
elastin reduces with a decrease in vessel diameter (15mg/g in small mesenteric
arteries) [33].
Collagen is a protein that is in a high content provides arterial stiffness and
limits arterial compliance. Collagen distribution reduces with a decrease of vessel
caliber (e.g. from 124 mg/g in carotid artery to 67mg/g in mesenteric arteries).
Collagen vascular wall content reduces towards periphery from 20% to 9% of the
wall volume over the mesenteric vasculature [33]. Collagen I and III are
expressed in media and highly present in adventitia. The basement membrane is
comprised of collagen IV.
9

The elastic fibers of the large elastic arteries provide an adequate arterial
compliance during systole. With aging, elastic laminae fragmentation process
occurs, redistributing mechanical load to collagen fibers that are stiffer by nature
[39]. Such impairments in vascular wall amplify systolic and pulse pressures that
provoke hypertension. Arterial remodeling in hypertension is characterized by
increase of media/lumen ratio with or without wall thickening (hypertrophic,
eutrophic) due to redistribution of SMCs or ECM proteins [40, 41]. Arterial wall
thickening occurs due to elastin degradation and collagen deposition. It reduces
arterial compliance and amplifies arterial fibrosis limiting distention of the
vascular wall. Therefore, pressure elevation is required to surpass arterial wall
stiffness.
Endothelial dysfunction is often, but not always, observed in arteries of
hypertensive subjects and plays a significant role in pathogenesis of arterial
remodeling [31]. Changes in blood flow and shear stress stimulate nitric oxide
(NO) release from endothelial cells (EC) that produce relaxation of VSMC and
vasodilation. EC layer damage facilitates impairments in endothelium- dependent
vasodilation due to the loss of NO production. In oxidative stress, the presence of
reactive oxygen species (ROS) decrease NO bioavailability due to the formation
of peroxynitrite that further exacerbates oxidative environment and EC injury [42].
In inflammation, EC produce cytokines [43] and growth factors: monocyte
chemotactic protein (MCP-1), TGF-β, C-reactive protein, plasminogen activator
inhibitor (PAI-1). They facilitate EC, VSMC, vascular pericytes proliferation.
Altered morphology with disruption of endothelial layer integrity, impaired
10

vasodilation and inadequate vasoconstriction significantly affect vascular tone
contributing to pathogenesis of hypertension [44].

Homocysteine
Homocysteine Metabolism
Homocysteine (Hcy) is a non-protein-coding α-amino acid that is synthesized
from dietary protein-derived methionine. Hcy is circulated in plasma in four forms:
about 1% is presented as the free thiol, 70-80% of circulated Hcy is bound to
plasma proteins (albumin), the rest of 20-30% of Hcy is bound to itself to form
Hcy dimers or combined with other thiols including cysteine forming Hcy-cysteine
mixed disulfide [4]. The term “total plasma (or serum) Hcy” (tHcy) is determined
as all four circulating forms of Hcy combined together [4].
Within the cells methionine converts to S-adenosylmethionine that is a
methyl group donor and is essential for various methylation reactions involving
DNA, amino acids and proteins [45]. S-adenosylhomocysteine is formed by the
methyl group donation of SAM to various substrates [45]. The excess of Hcy in
plasma is cleared via two essential pathways: remethylation and transsulfuration
pathways (Figure 1.). In remethylation pathway Hcy is converted back to
methionine with implication of two different enzymes: cobalamin-dependent
methionine synthase (MS) that is expressed in all tissues at very low levels and
betaine-homocysteine methyltransferase (BHMT) that is specific for kidney and
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liver and is produced at the very high levels [46]. The first enzyme utilizes
cobalamin (B12) as a cofactor and uses 5-methyltetrahydrofolate (5-MTHF) as the
methyl donor. 5-MTHF or active form of folate (B9) is synthesized from 5, 10methylenetetrahydrofolate by methylenetetrahydrofolate reductase (MTHFR).
Betaine-homocysteine methyltransferase (BHMT) that is only expressed in the
liver and kidney and is cobalamin-independent enzyme uses betaine as methyl
donor to remethylate Hcy back to methionine [47]. In transsulfuration that occurs
only in the small intestine, liver, pancreas and kidney a cofactor- vitamin B6 is
required to convert Hcy to cystathionine by cystathionine β- synthase (CBS) [48].
Cystathionine is hydrolyzed by vitamin B6- dependent cystathionine gammalyase (CSE) to cysteine that is used as a precursor for synthesis of antioxidantglutathione or vasodilator-hydrogen sulfide [48]. Nutritional deficiencies in vitamin
cofactors (B12, B9, and B6) and mutations in MTHFR, CBS and CSE enzymes are
the common causes of HHcy.

12
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Hyperhomocysteinemia
Epidemiology and Etiology of Hyperhomocysteinemia
The “normal” range for plasma tHcy is about 5-15 uM/L and
hyperhomocysteinemia (HHcy) is defined as an elevation of plasma tHcy level
above 15uM/L. HHcy is classified into moderate (16-30 uM/L), intermediate (31100 uM/L) and severe (more than 100 uM/L) HHcy [4].
Studies have shown that the prevalence of HHcy varies in different
countries and is estimated to be 6% in the Costa Rican population, 5% in the
United States, 77% in India, 27.5% in China and similar to that estimate in Brazil
and Lebanon [49, 50]. Patients with symptomatic atherosclerotic vascular
disease have shown 13-47% of HHcy prevalence. Several studies have shown
the elevation of tHcy plasma level with age due to age-associated decline in the
activity of enzymes that are involved in Hcy clearance and reduction in renal
function [51, 52]. The prevalence of HHcy is significantly higher in men than in
women that could be explained by the difference in muscle mass, lifestyle,
vitamin intake and sex hormones. A clinical study showed that four-month
treatment with ethinyl estradiol of male-to-female transsexulas significantly
reduced the Hcy plasma levels, however female-to-male transsexuals who
received androgen therapy expressed high plasma levels of Hcy [53]. In addition,
another clinical study confirmed the beneficial effect of estrogen replacement
therapy in reduction of Hcy plasma levels in postmenopausal women [54]. A
significant amount of studies have observed a strong positive correlation
14

between smoking, alcohol and coffee consumption and serum tHcy
concentrations [49, 55, 56]. Vermaak et al. have shown that cigarette smokers
have significantly lower levels of pyridoxal phosphate that contributes to Hcy
metabolism compared to non-smokers [57].

Genetic defects in enzymes that are involved in Hcy metabolism are
significant etiological factors that contribute to HHcy. The most common genetic
disorder that causes severe HHcy and homocysteinuria is homozygous
deficiency of CBS enzyme that is inherited as an autosomal recessive trait and
characterized by 40-fold elevation of fasting tHcy [4]. It occurs in 1 in 100,000 live
birth and defined by specific phenotype that includes lens disposition, bone
impairments, intellectual disability and premature atherosclerosis [58]. There are
60 described CBS enzyme mutations with I278T and G307S are being the most
common types [59]. The less common cases of severe HHcy are genetic
mutation in MTHFR, MS enzymes and genetic disorders in cobalamin
metabolism [60]. The most prevalent type of genetic enzyme disorder that has
been associated with moderate increase of plasma tHcy levels is a single point
mutation at nucleotide 677 (C-to-T substitution) in MTHFR gene that causes
about 50% decline in enzyme activity [61]. There is about 10-13% of prevalence
for this specific type of MTHFR mutation (TT genotype) in white population [62].
Nutritional deficiencies in vitamin cofactors such as folate (B9), cobalamin (B12)
and pyridoxal phosphate (B6) contribute to the development of HHcy [63]. It has
been reported that about two-thirds of HHcy is due to low blood concentrations of
mentioned vitamin co-factors [64]. Other case that could affect tHcy plasma
15

levels is kidney dysfunction. Clinical studies have shown that patients with
chronic renal diseases have elevated tHcy levels due to the impairments in Hcy
clearance by renal enzymes [65].

Epidemiological studies have described HHcy as an independent risk factor of
atherothrombotic vascular disease complications of which include stroke,
myocardial infarction, peripheral vascular disease, miscarriage, pulmonary
embolism and coronary heart disease [5, 6]. Several mechanisms have been
implicated in pathogenesis of HHcy-induced vascular disease: reactive oxygen
species activation, damage of vascular endothelium followed by endothelial
dysfunction and promotion of atherosclerosis, impairment in the process of
thrombolysis and hypercoagulation [66-68]. Sengwayo et al. have reported that
Hcy elevation was significantly associated with increase in both systolic and
diastolic blood pressure [6]. It has been implicated that the possible mechanisms
that are involved in HHcy- mediated hypertension could be ROS- induced
vascular endothelium damage that causes impairment in vasodilation, vascular
remodeling with elastin degradation and collagen deposition and VSMC hyperproliferation [6, 9]. A significant amount of other studies have also shown a
positive correlation between Hcy plasma levels and hypertension [7, 8, 69-73].
HHcy has been implicated to be involved in the initiation of vascular inflammation
as one of the key mechanisms that contributes to the development of arterial
vascular disease predisposing to hypertension [11, 74-76].
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Hyperhomocysteinemia and Inflammation

The Innate Immune System and Toll- Like Receptors (TLRs)

Inflammatory response is the reaction of the immune system to the presence of
antigens that involves two major systems innate and adaptive, that are closely
interact with each other. The innate immunity is the immediate response of the
immune system and the first line of defense against foreign antigens. The
epithelial cell barrier, pathogen recognition receptors (PRR) including Toll-like
receptors (TLRs), compliment system, monocytes and macrophages are the
major constituents of the innate immune system response [77]. It has been
proposed that TLRs and the innate immune system play a significant role in the
development of cardiovascular diseases. Sustained or excessive activation of
TLRs of the immune and vascular cells promote chronic vascular inflammation
that contributes to cardiovascular diseases. TLRs are expressed on immune
(macrophages, dendritic cells, monocytes) as well as non-immune cells
(endothelial cells, smooth muscle cells, fibroblasts, epithelial cells). TLR is a type
I glycoprotein receptor containing: 1) 20-27 extracellular leucine-rich repeat
domains that are required for ligand recognition, 2) transmembrane domain, 3)
intracellular Toll/interleukin-1 receptor (TIR) domain that activates downstream
signaling pathways [78, 79]. TLR signal transduction starts from TIR-mediated
recruitment of several adapter proteins: myeloid differentiation primary response
gene 88 (MyD88), MyD88-like adapter protein or also known as Toll-Interleukin I
receptor domain containing adaptor protein (TIRAP), TIR domain-containing
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adaptor protein inducing interferon-β (TRIF), TRIF related adaptor molecule
(TRAM) and sterile α- and armadillo-motif-containing protein (SARM) [80]. TIRAP
is necessary for activation of MyD88-mediated pathway and connects TIR
domain with MyD88 adapter protein. TRAM is required in TLR-4-mediated
activation of TRIF pathway. TIR-mediated recruitment of different adaptor
proteins promote: 1) the formation of “Myddosome” that involves MyD88-induced
mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light chainenhancer of activated B-cell (NF-kB) activation, 2) the assembly of “Triffosome”
for the activation of interferon regulatory factors (IRFs) and other kinases that are
involved in downstream signaling [81, 82]. In addition, TLR induces
inflammasomes that trigger caspase-1-mediated proteolytic cleavage of pro-IL-1β
and pro-IL-18 to activate mentioned cytokines (IL-1β, IL-18) [83]. Depending on
the type of TLRs, they sense the presence of bacterial, viral and fungal motifs or
pathogen-associated molecular pattern molecules (PAMPs). However, recent
studies have described that in addition to PAMPs, TLRs get activated by
circulating endogenous molecules or damage- associated molecular pattern
molecules (DAMPs) (Table 1; Goulopoulou et al. 2015) that are released from
damaged or dying cells [13, 14]. There are 13 TLRs that have been described in
mammals (TLR1-TLR10 in humans and TLR1-TLR9; TLR11-TLR13 in mice): cell
surface TLRs that sense the presence of microbial motifs (TLR- 1, 2, 4- 6 and 11)
and TLRs that localized to intracellular membranes and recognize viral or
bacterial nucleic acids (TLR- 3, 7- 9 and 13) [84-86].
The role of TLR- 4 that is ubiquitously present within the vasculature
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(endothelial cells, VSMC, fibroblasts) has been recently highlighted in sterile
inflammation [13, 14]. In contrast to others, TLR-4 is the most associated and
well-defined TLR that has been involved in etiology of hypertension. Bonfim et al.
have described the TLR-4 protein up-regulation in the mesenteric artery of
spontaneously hypertensive rat model compared to control that was
accompanied by increase in mean arterial blood pressure and circulating serum
levels of IL-6. However, treatment with anti-TLR-4 antibody reduced TLR-4, IL-6
expression and blood pressure [87]. Hernanz et al. have shown Angiotensin IImediated TLR-4 up-regulation that contributed to vascular inflammation,
endothelial dysfunction and vascular remodeling that are the hallmarks of
hypertension [88]. Dange et al. confirmed higher levels of TLR-4 in
paraventricular nucleus of spontaneously hypertensive rat model that was
correlated with inflammatory markers elevation and hypertension, but TLR-4
inhibition attenuated blood pressure, cardiac hypertrophy and reduced TNF-α, IL1β, NFkB and iNOS levels [89]. Schneider et al. have reported that patients with
TLR-4 single nucleotide polymorphism rs4986790 (TLR4 896A/G) had
significantly lower systolic blood pressure as well as pulse pressure compared to
TLR4 896A/A allele carriers [90]. Sollinger et al. have found that treatment with
inhibitor of endothelial nitric oxide synthase L-NAME induced DAMPs upregulation that was accompanied by ROS increase in TLR-4- dependent manner,
however there was reduction in arterial contractility in TLR-4-/- model [91]. Pineda
et al. in his study observed increase in TLR-4 in placentas of patients with
preeclampsia and even higher expression of TLR-4 in placentas of patients with
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chorioamnionitis compared to normal pregnancies. In addition, the authors have
found an elevation of TLR- 2-4 and TLR- 9 in placental villous stroma in patients
with preeclampsia [92]. There was an association confirmed between Asp299Gly
polymorphism in TLR-4 gene and reduction in C-reactive protein, prevalence of
coronary artery disease and diabetes [93]. A significant amount of studies have
also highlighted the role of TLR-4 in pathogenesis of atherosclerosis such as den
Dekker et al. have shown that TLR-4 signaling pathway plays role in mast cellmediated VSMC apoptosis that contributes to atherosclerotic plaque
destabilization [94]. Several other studies have observed that TLR-4 activation
promotes macrophage differentiation into foam cells and apoptosis [95-97],
induces SMC proliferation [98] and pro- inflammatory activation of endothelial
cells [99-101].
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Macrophages are significant constituents of the innate immune system
that promote inflammation, vascular remodeling, engaging matrix
metalloproteinases (MMPs) and impair vascular reactivity through increased
ROS production. Macrophages play a major role in IL-1β, IL-6 and TNF-α
cytokine release.
Pro-inflammatory Cytokines that Contribute to Vascular Inflammation and
Hypertension
Interleukin-1β (IL-1β)
IL-1β is primarily released by immune cells (monocytes and macrophages) and
by other cell types including vascular EC and renal tubular epithelial cells [102,
103]. IL-1β acts as pro-inflammatory cytokine through stimulation of specific cell
surface receptor IL-1 type 1 receptor (IL-1RI) that is located on immune cells
(macrophages, monocytes and lymphocytes) as well as on vascular cells (EC
and SMC). Ligand- receptor (IL-1β- IL-1RI) interaction recruits accessory protein
(IL-1RAcP) that provides stronger ligand-receptor connection. Several adapter
proteins such as myeloid differentiation factor 88, TNF receptor-associated factor
6 and IL-1R-associated kinase are engaged by accessory proteins followed by
JNK, p38 MAPK, activator protein-1 (AP-1) and transcription factor NF-kB
activation that induce pro-inflammatory gene up-regulation [104]. IL-1β is an
immediate response cytokine that promotes release of other downstream
cytokines such as: IL-6 and IL-17 that stimulate proliferation of T helper 1 and T
helper 17 cells contributing to pathogenesis of hypertension [105, 106]. Studies
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have described the direct effect of IL-1β on vascular wall suggesting that IL-1β
infusion facilitates impaired endothelial-dependent relaxation response to
acetylcholine compared to vessels incubated with vehicle [107]. It was shown
that IL-1β promotes reactive oxygen species production, as IL-1β treated vessels
expressed higher levels of iNOS and superoxide than controls [108]. Dalekos et
al. have shown that patients with essential hypertension have higher circulating
levels of IL-1β compared to normotensive patients [109]. Monocytes isolated
from peripheral blood of hypertensive patients produce higher levels of IL-1β in
response to Angiotensin II or LPS stimulation compared to monocytes isolated
from normotensive individuals [110]. Dorrance et al. have reported that IL-1β
treatment induced greater vasoconstriction in aortas isolated from hypertensive
rats compared to normotensive rats [111].
Interleukin 6 (IL-6)
IL-6 is a 21kDa glycoprotein that is released by variety of cells: dendritic cell,
macrophages, T helper 1 cells, monocytes and vascular cells. The IL-6
interaction with IL-6 receptor induces several effects on target organs including
neutrophil chemotaxis, polarization of CD4+ T cells and bone resorption. IL-6 upregulation has been associated with several conditions including atherosclerosis,
hypertension, autoimmune diseases and malignancies. Studies have shown a
positive correlation of IL-6 plasma levels with blood pressure elevation and IL-6
levels reduction after angiotensin II receptor blockade [112]. The Angiotensin II
treatment up-regulates plasma level of IL-6 in humans and this is prevented by
treatment with spironolactone [113]. Lee et al. have confirmed that IL-6-/- mice are
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resistant to developing hypertension and albuminuria after angiotensin II
treatment and excessive salt intake compared to control group [114].
Tumor necrosis factor-α (TNF- α)
TNF- α is released by diverse cells of the immune system including
macrophages, T cells and by vascular cells such as endothelial cells, fibroblasts.
TNF- α activates TNF receptor 1 and TNF receptor 2 inducing activation of
death/survival pathways, NADPH oxidase and nuclear factor kappa B (NFkB)
signaling pathway [115]. TNF- α-mediated NADPH oxidase and NFkB activation
promote rise in chemokine and adhesion molecule expression, sodium retention
by the kidney and vascular remodeling [116]. Studies have shown that TNF- α
inhibits endothelial nitric oxide synthase (eNOS) promoter affecting mRNA and
protein expression of eNOS reducing the production of NO that impairs
vasodilation and promotes vasoconstriction [117, 118]. In kidneys NO inhibits
sodium reabsorption and the absence of NO promotes sodium retention. Studies
suggest that Angiotensin II infusion stimulates T cells to release TNF- α and
inhibition of TNF- α protects from Angiotensin II-mediated hypertension [119].
TNF- α-/- mice are resistant to Angiotensin II-induced blood pressure elevation
and express reduction of left ventricular hypertrophy [120].
The Adaptive Immune System
Unlike the innate immune system, the adaptive immunity is highly specific to
unique foreign antigen and is designed to create immunological memory that
allows the enhanced immune defense against recognized pathogen. Antigen23

presenting cells (APCs: macrophages, dendritic cell, B-cells) represent foreign
antigens in major histocompatibility complexes (MHC), such that MHC-I attracts
CD8+ T- cells and MHC-II activates CD4+ T- cells [77]. T- cells express T- cell
receptor on their surface that interacts with MHC of the APC, leading signal-1 Tcell activation. Signal-2 or T- cell co-stimulation is essential for the full T- cell
activation and is induced by T- cell CD28 and APCs B7 ligands (CD80, CD86)
interaction. Studies suggest that T- cell co-stimulation plays a major role in
pathogenesis of hypertension such that hypertension has been associated with
up- regulation of CD86 in spleen and lymph node dendritic cells and B7 liganddeficient mice are resistant to blood pressure elevation [77, 121]. The full T- cell
activation induces a complex of signaling events including effector T- cell
proliferation, cytokine production and T- cell migration from secondary lymphoid
organs (spleen, lymphoid nodes) to sites of tissue damage that is guided by
cytokines and chemokines released from affected tissues. The effector T- cells
that are arrived to peripheral tissues further orchestrate the inflammatory
response releasing variety of mediators [122]. The effector T- cell response is
limited in duration and the majority of the effector T- cells undergo programmed
cell death, the rest are destined to become central memory cells that migrate
back to secondary lymphoid organs or stay at the peripheral sites to become
effector memory cells. CD4+ effector T- cells have four specific phenotypes: Thelper 1 cells that are produced in defense to intracellular bacteria and virus and
release interferon-γ, T helper 2 cells produced against allergens and helminthes,
T helper 17 cells that protect against extracellular bacteria and fungi and the
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fourth phenotype includes regulatory T- cells that release anti-inflammatory
cytokine IL-10 and suppress T helper 1 and 2- mediated immune responses
[123]. CD8+ effector T- cells release cytotoxic molecules (perforin, granzyme B),
cytokines and are classified in the same manner as CD4+ cells (i.e. TC1, TC2,
TC17 and cytotoxic regulatory T- cells).
The Role of Hyperhomocysteinemia in Inflammatory Response
A significant number of studies have described inflammation as one of the toxic
effects of Hcy. Zhang et al. reported that plasma Hcy was positively correlated
with plasma pro-inflammatory cytokine and chemokine (IL-6, TNF- α and MCP-1)
levels and promoted inflammatory monocyte differentiation [11]. Zanin et al. have
shown that HHcy is involved in the synthesis and secretion of IL-1β in murine
macrophages via NF-kB that is inflammatory cytokine transcription factor [124].
Han et al. have observed endothelial cell inflammatory injury through activation of
NF-kB and cytokine IL-6 up regulation in HHcy [125]. Several in vitro studies
have shown inflammatory markers up-regulation in HHcy, including activation of
NF-kB [10, 126]. Scherer et al. have also observed mild HHcy-mediated
augmentation of inflammatory cytokine production (IL- 1β, IL- 6, TNF- α, MCP-1)
in serum and different organs [12]. Wang et al. have reported Hcy treatmentinduced monocyte chemoattractant protein- 1 (MCP-1) elevation in macrophages
via NF-kB activation [127]. Lee et al. described that HHcy facilitates (MMP- 9)
production in murine macrophages the activity of which is involved in vascular
remodeling [128]. Gao et al. observed that combined treatment with Hcy and LPS
led to macrophage polarization from anti-inflammatory (M2) to pro-inflammatory
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subtype (M1) that promotes the progression of atherosclerosis [129].
Apart from been involved in innate immune response, HHcy has been also
shown to play role in adaptive immune system. Feng et al. have observed that
HHcy increases the production of ROS from T lymphocytes and reduces
proliferation and function of regulatory T- cells that have anti-inflammatory
properties [130]. Zhang Q et al. have described that Hcy elevation promotes Tcell and lipopolysaccharide-induced B-lymphocytes proliferation that contribute to
chronic inflammatory progression of atherosclerosis [131, 132].

Hyperhomocysteinemia and Mitochondrial Dysfunction

Mitochondrial Dynamics and Cardiovascular Diseases

Mitochondria are the cell organelles that function to provide energy generation,
regulation of cell survival (apoptosis), synthesis of reactive oxygen species and
control of intracellular Ca2+ concentration [133]. Mitochondria preserve and
constantly maintain their function in response to various changes in the cellular
environment through mitochondrial dynamics. Mitochondrial dynamics is defined
as mitochondrial adaptation to intracellular changes where mitochondria
constantly undergo through fusion and fission processes. Mitochondrial fusion
allows union of two or more mitochondria to form one and as a result
mitochondria acquire tubular or elongated shape. The process of fusion is
regulated by outer mitochondrial proteins: mitofusin 1 and 2 (Mfn-1, Mfn-2) and
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inner mitochondrial protein: optic atrophy 1 (Opa-1) protein [134]. Studies have
observed that Mfn-1 and Mfn-2 down- regulation promotes mitochondrial fission
[135]. Cardiac specific Mfn-1 knockout mice expressed small round-shape
fragmented mitochondria [136], however cardiac specific Mfn-2 knockout mice
exhibited enlarged mitochondria in the heart [137]. Mfn-2 participates in
mitophagy or the process of damaged mitochondria elimination, where Mfn-2 is
phosphorylated by PTEN-induced kinase 1 (PINK 1) that attracts Parkin that
further orchestrates mitochondria quality control process [138]. Overexpression
of inner mitochondrial membrane protein Opa- 1 facilitates the formation of
elongated mitochondria and enrichment of mitochondria network, however, Opa1 down- regulation promotes disintegration of cristae and excessive
mitochondrial fragmentation [139].
Mitochondrial fission is the process of mitochondria disintegration with
small spherical- shaped mitochondria formation. Upon activation mitochondrial
fission protein Drp- 1 (dynamin related protein 1) shifts from cytosol to
mitochondrial fission sites, where it recruits outer mitochondrial membrane
protein- mitochondrial fission factor (Mff) to further facilitate fission process.
Mitochondrial fission 1 (Fis- 1) is outer mitochondrial membrane protein that is
highly required for the process of mitochondrial fragmentation. The initiation of
mitochondrial fission starts from mitochondria constriction by endoplasmic
reticulum tubules that orient and define the sites of division followed by Drp-1mediated scission of mitochondria [140]. Drp-1 is an 80 kDa dynamin GTPase
protein that is primarily located in cytosol as dimer/tetramer and upon activation
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shifts to the sites of division on mitochondria for further mitochondria dissection.
Studies suggest that due to the lack of mitochondrial targeting sequence, Drp-1
requires a receptor to be recruited to the outer mitochondrial membrane for
mitochondrial fission. Fis-1 is a 17-kDa protein that is attached to the outer
mitochondrial membrane and it was a potential candidate for the Drp-1 receptor
[141]. Although, studies have confirmed that Fis-1 overexpression facilitates
mitochondrial fission, Fis-1 protein knockdown did not affect recruitment of Drp-1
to mitochondria and mitochondrial fission respectively [142]. However, studies
have shown that the other outer mitochondrial membrane protein Mff acts as
Drp-1 receptor due to the fact that Mff knockdown suppressed Drp-1
translocation on mitochondria, but Mff overexpression was found to promote
mitochondrial fission with excessive Drp-1 recruitment to mitochondria [142].
Both, mitochondrial fusion and fission are required for the normal function
of mitochondria. Mitochondrial fusion allows maintenance of mitochondrial
membrane potential; redistribution of protein components, mitochondrial DNA
within mitochondrial network; mitochondrial DNA repair. During energy
deprivation mitochondrial fusion helps to maintain adequate oxidative
phosphorylation. On the other hand, mitochondrial fission is required for cell
division, movement of mitochondria within cytoplasm, elimination of
damaged/senescent mitochondria by mitophagy.
The impairments in mitochondrial dynamics have been associated with the
development of several cardiovascular disease including heart failure, cardiac
hypertrophy, atherosclerosis, diabetes, hypertension and ischemic heart disease
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[143, 144]. In post- myocardial infarction there is excessive mitochondrial
fragmentation in rat hearts, which was associated with Opa-1 reduction [145].
Loss of Mfn-2 has been shown to promote mitochondrial membrane
permeabilization, followed by cytochrome c release that contributed to
cardiomyocyte death [146]. It was found that cardiomyocytes exhibited
mitochondrial fragmentation and dysfunction after 30 minutes of hypoxia followed
by normoxia, however Mfn- 1 or Mfn- 2 overexpression inhibited mitochondrial
membrane permeabilization and cell death. Treatment with Drp-1 inhibitor (Mdivi1) prevented mitochondrial dysfunction and cell death in vitro and decreased
myocardial infarct size in vivo [147]. The other work described that treatment with
α- agonist phenylephrine reduced Mfn- 2 expression and elevated mitochondrial
fission proteins including Drp- 1 and Fis- 1 [148]. Venous endothelial cells that
were isolated from patients with diabetes mellitus expressed high levels of Fis- 1
protein suggesting the presence of mitochondrial fission. High glucose treatment
of human aortic EC facilitated elevation of fission proteins Drp-1 and Fis- 1 that
was accompanied by mitochondrial ROS production and reduction of eNOS.
However, Fis- 1/Drp- 1 inhibition prevented impairments in mitochondrial
dynamics followed by ROS reduction and eNOS activation [149]. Studies have
reported that mitochondrial dynamics impairment contributes to pathogenesis of
pulmonary arterial hypertension (PAH) [144, 150]. Marsboom et al. have shown
that Drp- 1 elevation promotes pulmonary artery smooth muscle cell
hyperproliferation that contributes to PAH, however Drp- 1 inhibition with Mdivi- 1
suppresses mitochondrial fission and smooth muscle cells hyperproliferation
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preventing PAH. Mdivi- 1 treatment also improved exercise capacity, right
ventricular function and hemodynamics in PAH [150].
Mitochondrial Dynamics and Hyperhomocysteinemia
Several studies have highlighted the role of HHcy in mitochondrial dynamics
alteration. Kumar et al. have observed altered mitochondrial membrane potential
and fragmentation of the mitochondrial network in S- adenosylhomocysteine and
Hcy- treated cells as compared to control cells [151]. In the same study, the
elevation of Fis-1 and dynamin-1 proteins in S- adenosylhomocysteine and Hcytreated cells was confirmed by PCR, suggesting that HHcy favors mitochondrial
fission that could be a compensatory mechanism in response to mitochondrial
stress allowing elimination of damaged mitochondria [151]. Kalani et al. have
proposed the novel mechanism of bone remodeling in HHcy, where HHcymediated mitochondrial oxidative stress altered mitochondrial dynamics and
mitochondrial epigenetics that contributed to increase in MMPs/TIMPs and
collagen/elastin ratio promoting bone remodeling [152]. Ganapathy et al. for the
first time described mitochondrial fission as a novel mechanism of Hcy toxicity to
neurons [23]. In this study, it was found that there was an up-regulation of Fis-1,
Opa-1 and cleaved caspase- 3 protein expressions in neural retinas of CBS+/mouse model with mild HHcy. Mitochondria of CBS+/- mouse model in retina was
fragmented, reduced in size, and increased in quantity as compared to control
group [23].
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Mitochondria- Mediated Cell Death and Cardiovascular Diseases
Apoptosis is a highly regulated form of cellular suicide that is morphologically
characterized as cell shrinkage, membrane blebbing, DNA fragmentation,
chromatin condensation and cellular elimination via phagocytosis. Programmed
cell death includes two pathways: the extrinsic and intrinsic pathways. The
extrinsic pathway is triggered by ligand binding (FasL) to the cell surface TNF
death- receptor, recruiting Fas- associated death domain protein (FADD) that
activates caspase- 8 followed by stimulation of caspase- 3 [153]. The effector
caspase- 3 promotes proteolytic cleavage of key structural and functional
proteins, including DNA fragmentation factor (DFF) and poly ADP ribose
polymerase (PARP) in the nucleus, facilitating DNA fragmentation [153]. The
intrinsic cell death pathway is initiated in mitochondria and is triggered by ROS,
Ca2+ overload, mitochondrial membrane depolarization. B- cell lymphoma 2 (Bcl2) family proteins: Bax and Bak that are classified as pro- apoptotic proteins are
highly required for the intrinsic apoptosis regulation [154]. Upon activation Bax is
translocated from cytosol to mitochondria where it regulates mitochondrial outer
membrane permeabilization (MOMP) followed by cytochrome c release that
promotes apoptosome formation (cytochrome c - apoptotic protease- activating
factor 1- procaspase- 9 complex). This, in turn activates caspase- 9, triggering
caspase- 3 that contributes to DNA fragmentation.
A significant amount of studies have implicated that mitochondrial
dynamics plays a unique role in mitochondria- mediated cell death. Mitochondrial
fusion/fission imbalance has been shown to promote sustained mitochondrial
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fragmentation leading to mitochondrial apoptosis initiation [155]. Several studies
have described the mitochondrial fission protein interaction and co- localization
(Drp-1) with pro- apoptotic proteins (Bax) in mitochondrial division foci suggesting
that mitochondrial dynamics participates in mitochondria- mediated cell death
[156].
Littlewood et al. have reported that apoptosis of endothelial cells,
macrophages and vascular smooth muscle cells facilitates plaque growth and
promote plaque rapture in atherosclerosis [157]. Mitochondria are known to be a
primary intracellular source of ROS. Excessive mitochondrial ROS production
promotes mitochondrial DNA damage, mitochondrial DNA mutation and initiation
of mitochondrial apoptosis all contributing to cardiovascular diseases [158]. The
increase of oxidized LDL induces mitochondria- mediated apoptosis in
endothelial cells in diabetes type 2 [159]. Hyperglycemia in diabetes upregulates BAX expression, promotes opening of mitochondrial transition pore
followed by release of pro- apoptotic molecules that leads to endothelial cell
apoptosis [21, 160, 161].
Mitochondrial Apoptosis and Hyperhomocysteinemia
A significant amount of studies have highlighted the role of HHcy in mitochondriamediated cell death initiation in different cell types. Lee et al. have shown that
Hcy treatment facilitated caspase- dependent apoptosis in human umbilical vein
endothelial cells that was accompanied by ROS production, cytochrome c
release, overexpression of pro- apoptotic molecules: p53 and Noxa [162]. In the
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same study it was confirmed that the NO donor S- nitroso- Nacetylpenicillamine, adenoviral transfer of inducible NO synthase gene, and
antioxidants (α- tocopherol, superoxide dismutase) suppressed ROS production,
Noxa expression and apoptosis in HHcy [162]. Sipkens et al. have reported that
Hcy treatment of rat cardiomyoblast cells and adult rat cardiomyocytes induced
apoptosis with ATP depletion and excessive NOX- 2 and ROS production in
concentration- dependent manner [163]. Buemi et al. have observed that the
addition of 10 mM/L of Hcy to the smooth muscle cell culture medium facilitated
smooth muscle cell hyperproliferation and death through apoptosis [164]. There
was a positive correlation between Hcy concentration and percentage of
apoptotic cells and cells with necrotic morphology, however the addition of folic
acid to the culture medium significantly reduced Hcy concentration in medium as
well as apoptosis [164]. Tyagi N et al. have reported that Hcy treatment of rat
heart microvascular endothelial cells (MVEC) induced ROS production leading to
loss of mitochondrial membrane potential, decrease in Bcl2/Bax ratio, cytochrome
c release, and caspase- 9, caspase-3 elevation that contributed to DNA
fragmentation [165]. Treatment of MVEC with caspase- 9 small interfering RNA
suppressed HHcy- mediated mitochondrial apoptosis in endothelial cells [165].
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CHAPTER III

HYPOTHESIS AND SPECIFIC AIMS

Key Objective
The objective of this study was to define the mechanisms of homocysteine
toxic effect on vascular wall that promote vascular remodeling and hypertension
and explore the role of toll- like receptor 4 mutation in alleviation of homocysteine
negative effects.

Hypothesis
HHcy-induced TLR-4 activation promotes vascular inflammation and
mitochondrial dysfunction that lead to inward vascular remodeling inducing
hypertension. TLR-4 mutation attenuates vascular inflammation and
mitochondrial dysfunction that suppress hypertension (Figure 2.)

Specific Aims
Specific Aims 1: To determine whether HHcy impairs mitochondrial dynamics
by increasing mitochondrial fission and reducing mitochondrial fusion that lead to
vascular remodeling.
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Specific aim 1 will be discussed in Chapter IV
Specific Aims 2: To determine whether HHcy activates TLR- 4 mediated
inflammatory pathway with cytokine up- regulation (IL-1β, IL-6 and TNF-α)
inducing vascular inflammation that contributes to hypertension.

Specific Aims 3: To determine whether HHcy- induced TLR-4 activation
promotes mitochondria- mediated cell death followed by inward vascular
remodeling facilitating hypertension.
Specific aims 2 and 3 will be discussed in Chapter V.
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Figure 2: Schematic Representation of Overall Hypothesis
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CHAPTER IV

MITOCHONDRIAL FRAGMENTATION FACILITATES MESENTERIC ARTERY
REMODELING IN HYPERHOMOCYSTEINEMIA

Introduction
Clinical studies show that patients with hypertension and mesenteric
artery occlusion are represented with high plasma homocysteine (Hcy) levels
[7, 8, 166]. Based on the literature, Hcy elevation has been implicated in the
development of endothelial dysfunction [167-169] and mesenteric artery
remodeling, however the mechanisms are not well defined. The thiol group of
Hcy is auto-oxidized to reactive oxygen species (ROS), amplifying the level of
oxidative stress (OS) [170] and leading to inflammation. It has been reported that
the levels of superoxide and peroxynitrite (OONO- formed by the interaction of
superoxide and nitric oxide) are increased in HHcy in rat aorta and are mediated
by NADPH oxidase (NOX) [171]. Under pathological conditions, the activation of
NOX in vascular cells leads to excessive superoxide ion production, contributing
to vessel injury [172, 173]. The increase in reactive oxygen species (ROS) is
accompanied by a compensatory increase in the antioxidant enzymes e.g.
superoxide dismutase (SOD) [174]. Hence, the increased levels of superoxide
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dismutase (SOD) and NOX are indicative of oxidative stress.
The other factor that contributes to endothelial dysfunction is decrease in
endothelial nitric oxide synthase (eNOS- the enzyme catalyzing the production of
NO from L- arginine) bioavailability that occurs in the presence of circulating
ROS. Impaired endothelium with reduced eNOS is incapable to produce required
vasodilators such as NO for the appropriate artery/arteriole vasodilation.
Previous studies have reported that HHcy promotes endothelial dysfunction
[167-169]. In addition to eNOS, connexins play an important role in the
maintenance of the endothelium integrity and any disturbance in the levels of
connexins is an indication of vasomotor tone disruption [175].
Despite abundant literature demonstrating that elevated homocysteine
induces oxidative stress behind mesenteric artery remodeling, the role of
mitochondrial dynamics has been explored only a little [23]. Mitochondria are the
cell organelles whose primary functions are energy production, regulation of cell
survival (apoptosis), ROS production and regulation of intracellular Ca2+ [133].
Mitochondria constantly undergo fission and fusion processes in response to
physiological stimulus and stress [22]. Mitochondrial fission is the process of
mitochondrial disintegration forming two or more separate mitochondrial
compartments regulated by dynamin related protein 1(Drp1), fission-1(Fis-1) and
mitochondrial fission factor (MFF). Mitochondrial fission process also contributes
to quality control by enabling the removal of damaged mitochondria. Elimination
of damaged mitochondria is also called mitophagy. On the other hand,
mitochondrial fusion is union of two or more mitochondria within a cell to form
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one, regulated by inner mitochondrial membrane protein optic atrophy-1(OPA-1)
and two outer mitochondrial membrane proteins: mitofusin- 1and
mitofusin- 2 (Mfn-1, Mfn-2). Excessive mitochondrial fission and decreased
mitochondrial fusion leads to mitochondrial fragmentation. Accumulation of
damaged mitochondria and sustained fission facilitate the release of proapoptotic molecules that initiate cell death. Impaired mitochondrial dynamics is
also associated with cardiovascular diseases and diabetes [19-22]. Although
HHcy causes mitochondrial fission [23], it is unclear whether it contributes to
endothelial cell damage and peripheral vascular remodeling. Therefore, we
hypothesize that HHcy impairs mitochondrial dynamics by increasing
mitochondrial fission that promotes endothelial cell damage and endothelial
dysfunction, facilitating peripheral vascular remodeling.

Materials and methods

Animal models
C57BL/6J (WT), cystathionine β- synthase deficient mice (CBS+/-) with
genetic mild HHcy; C3H/HeJ (C3H) as per Jackson Laboratories (Bar Harbor,
ME), these mice have a mutation in the TLR- 4 receptor and previous reports
show that TLR- 4 mutants have reduced oxidative stress [176]; and mice with
combined genetic HHcy and TLR-4 mutation (CBS+/-/C3H) were used in the
present study. The age of the animals was 12 weeks and the body weight was
25-30 g. The mice were purchased from Jackson Laboratories (Bar Harbor, ME,
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USA). All standard procedures and experiments with animals were followed in
agreement with the National Institute of Health and approved by Institutional
Animal Care and Use Committee (IACUC), University of Louisville.
Genotyping
To confirm the background of CBS+/- heterozygous mice the protocol for
genotyping were used as per Jackson Laboratories. Shortly, the samples of mice
tails were collected for DNA extraction. DNA was used to amplify with
cystathionine β- synthase primer sets by PCR. The PCR product samples were
run on 1.2% agarose gel (prepared in TAE buffer, pH 8.4) with ethidium bromide.
The images were recorded in gel documentation system (Bio- Rad, Hercules,
CA, USA). To confirm TLR-4 mutation in C3H/HeJ mice the respective protocol
of RFLP-PCR was used [176]. Shortly, DNA extracted from mice tails was
amplified with specific TLR-4 set of primers (Table 2). PCR products were
digested with NLa III restriction enzyme (RE) for overnight at 370C. The RE
digestion products were loaded on 10% PAGE gel and run at 80 Volts. The gel
was incubated with 1X TAE buffer containing ethidium bromide. The images
were made in gel documentation system (Bio- Rad, Hercules, CA, USA). Mutant
TLR-4 gene includes CATG sequence that is cut by RE, yielding 96 and 108 bps
bands, while absence of TLR-4 mutation is confirmed by undigested products at
204 bps. To confirm the genetic background of CBS+/-/C3H mice we first
determined CBS gene deficiency in their DNA samples that were selected for
further detection of TLR-4 mutation.
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Western blot analysis
The SMA protein content was extracted using mix of RIPA buffer (Boston
BioProducts, MA, USA), PMSF (Calbiochem, La Jolla, CA, USA) and protease
inhibitor (Sigma Aldrich, St. Louis, MO, USA). The protein extract was incubated
for overnight at 40C with shaking and centrifuged at 13 000 rpm for 20 min. The
supernatant was collected in another tube for protein estimation using Bradforddye method (Bio-Rad, CA, USA). The prepared protein lysate (60 ug) was heated
at 950C for 5 min and loaded on polyacrylamide gel with SDS in running buffer
and run at constant current (100 Volts). For protein transferring to PVDF
membrane electro transfer apparatus (Bio-Rad) was used. After transferring, the
membranes were blocked in 5% nonfat milk for 1 hour at room temperature,
followed by overnight incubation with primary antibodies (anti- Nox4, SOD-1,
SOD-2, CBS, eNOS, Mfn-2, Drp-1; Santa Cruz Biotechnology, Dallas, TX, USA;
Abcam, Cambridge, MA, USA.) at 40C. After washing with TBS-T buffer,
membranes were incubated with secondary antibodies (horse radish peroxidaseconjugated goat anti-mouse, goat anti- rabbit, and rabbit anti- goat IgG; Santa
Cruz Biotechnology, Dallas, TX, USA) for 1 hour at RT with 1:5000 dilution
followed by washing step. The membranes were developed with ECL Western
blotting detection system (GE Healthcare, Piscataway, NJ, USA) and all images
were recorded in the gel documentation system ChemiDoc XRS (Bio-Rad,
Richmond, CA, USA). The membranes were stripped with stripping buffer
(Boston BioProducts, Ashland, MA, USA) followed by blocking step with 5% milk
for 1 hour at RT. After washing step membranes were reprobed with anti41

GAPDH antibody (Millipore, Billerica, MA, USA) as a loading control protein. The
data were analyzed by Bio-Rad Image Lab densitometry software and
normalized to GAPDH bands.
qPCR
To assess mRNA expression of different genes in the SMA, RNA was
isolated with TRIzol® reagent (Life Technologies, Carlsbad, CA, USA) according
to manufacturer's instructions. The RNA quantification and purity was assessed
by nanodrop-1000 (Thermo Scientific, Walthan, MA, USA). Aliquots (2μg) of total
RNA were reverse- transcribed into cDNA using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) according to
manufacturer’s protocol. The q-PCR was performed for different genes (Mfn- 2,
Drp- 1), in a final reaction volume of 20 ul containing 10 ul PerfeCTa SYBR
Green SuperMix, Low ROX (Quanta Biosciences, Gaithersburg, MD), 6 ul
nuclease free water, 2ul cDNA, 40 picomoles of forward, and reverse primers. All
sequence- specific oligonucleotide primers (Invitrogen, Carlsbad, CA, USA) are
presented in (Table 2). The data was represented in fold expression, calculated
as the cycle threshold difference between control and sample normalized with
housekeeping gene Rn18s.
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Table 2

Immunohistochemistry

The SMA tissue was immersed in tissue- freezing medium (Triangle
Biomedical Sciences, Durham, NC, USA) in disposable plastic tissue- embedding
mold (Polysciences Inc., Warrington, PA, USA). The tissue blocks were kept at 800C until use. To obtain 5 um thickness sections Cryocut (CM 1850; Leica
Microsystems, Buffalo Grove, IL, USA) was used. Tissue sections were placed
on polylysine coated slides (Polysciences, Inc., Warrington, PA, USA). Tissue
sections were incubated with permeabilization solution (0.2 g Bovine Serum
Albumin, 3 ul Triton X-100 in 10ml 1X PBS) for 1 hour at RT followed by washing
step with 1X PBS. The sections were incubated with primary antibody (antiCD31, connexin 40, Mfn-2, Drp-1) with 1: 250 dilution for overnight at 40C. After
washing with 1X PBS the slides were incubated with fluorescently labeled
secondary antibodies (gout anti-mouse Alexa flour 488 and gout anti-rabbit
Texas red; Invitrogen, Waltham, MA, USA) with 1: 500 dilution for 1 hour at RT
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followed by DAPI staining with 1: 10,000 dilution for 20 min at RT. After washing
step slides were mounted with mounting medium and visualized using laser
scanning confocal microscope (Olympus Fluo View 1000; Center Valley, PA,
USA). The images were analyzed by measuring fluorescence intensity with
Image Pro-Plus software (Media Cybernetics, Rockville, MD, USA).

Masson’s trichrome staining

The same protocol as written above was used to get tissue frozen
sections. The slides with tissue were hydrated with distilled water (100%, 90%
and 70%) and placed in Bouin’s Fluid at 560C for 1 hour. After washing with tap
water for 5 minutes sections were placed in Working Weigert’s Iron Hematoxylin
Stain (Weigert’s Iron Hematoxylin A+ Weigert’s Iron Hematoxylin B) for 10
minutes. After washing in tap water for 10 minutes tissue sections were stained
in Biebrich Scarlet- Acid Fuchsin solution for 7minutes. After 30 seconds of
washing in distilled water, slides were placed in PhosphotungsticPhosphomolybdic Acid solution for 5 minutes and after that stained in Aniline
Blue Stain solution for 7minutes. Then tissue sections were placed in 1% Acetic
Acid solution for 1 minute, rinsed in distilled water for 30 seconds and dehydrated
in anhydrous alcohol for 1min each (70%, 90% and 100%). After that slides were
cleared in clearing reagent (Xyline) three times for 1min each and mounted. The
images were obtained by using light microscopy (x20 objectives, QCapture Pro).
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The images were analyzed by measuring the color intensity with image analysis
software (Image Pro-Plus, Media Cybernetics).

Statistical analysis

Statistical analysis was performed with Primer of Biostatistics 7.0
(McGraw-Hill, NY, USA). To determine the significance, we used one-way
analysis of variance (ANOVA) followed by multiple comparison test (Holm test)
between the groups. The difference was considered significant when p< 0.05.
Values are presented as mean ± SEM (n=4).

Results
Genotyping for WT, CBS+/-, C3H and CBS+/-/C3H mice
For genotype analysis the Jackson Laboratory protocol was followed. CBS+/and CBS+/-/C3H mice had two bands located at 450 and 308 bps while CBS+/+
mice had band located at 308 bps when primers specific for CBS gene were
used (Fig.3A). TLR- 4 mutants (C3H and CBS+/-/C3H) had bands located at 96
and 108 bps, whereas non-mutants (WT, CBS+/-) had single band at 204 bps
(Fig.3B) when PCR-RFLP was used with TLR-4 primers.
Western blotting for cystathionine β- synthase (CBS) protein expression
CBS+/- and CBS+/-/C3H exhibited reduced CBS protein expression in the SMA
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tissue as compared to control group (Fig.4 A, B).
HHcy evoked oxidative stress in the mesenteric artery
We have found that Nox4 (oxidative stress marker), SOD-1 and SOD-2
(antioxidants) were up regulated in the SMA of CBS+/- mice as compared to WT
mice. The protein expression of Nox4 and SOD-1 were decreased in C3H as in
CBS+/-/C3H mouse models compared to CBS+/- mice. Interestingly, the
expression of SOD-2 (mitochondrial antioxidant) was increased in C3H mouse
model compared to control (Fig.5 A, B).
Altered mitochondrial dynamics in HHcy
To evaluate the effect of HHcy and oxidative stress on mitochondrial dynamics
we analyzed two major proteins: Mfn-2 (regulates mitochondrial fusion) and Drp1 (regulates mitochondrial fission) by western blot, qPCR and
immunohistochemistry. Western blot data (Fig.6 A, B) showed that the protein
expression of Mfn-2 was decreased in CBS+/- mouse model compared to WT
mice. Drp-1 protein expression was significantly up regulated in CBS+/- mice as
compared to WT mice. The fusion was increased and fission was down regulated
in CBS+/-/C3H mice compared to CBS+/- mice. Using real time qPCR (Fig.7 A,
B) we confirmed that Mfn-2 was also down regulated in CBS+/- mice as
compared to WT and CBS+/-/C3H mice and Drp-1 was also up regulated in
CBS+/- mice as compared to WT and CBS+/-/C3H mice. By
Immunohistochemistry (Fig.8 A, B) we determined that the intensity of Mfn-2 was
decreased in the mesenteric artery of CBS+/- mice as compared to WT, CBS+/46

/C3H mice. In addition, the intensity of Drp-1 in the mesenteric artery was
increased in CBS+/- and CBS+/-/C3H mice as compared to WT mice. These
results suggest HHcy- mediated prevalence of mitochondrial fission over
mitochondrial fusion in CBS+/- mice that contributes to mitochondrial
fragmentation.
HHcy induced endothelial cell layer damage
To determine whether elevated homocysteine contributes to endothelial cell layer
damage, CD31 and connexin 40 intensity levels were observed (Fig.9 A, B). By
immunohistochemistry we have determined that the intensity of CD31 was
decreased in CBS+/- mice as compared to WT, C3H and CBS+/-/C3H mice. The
intensity of connexin 40 (gap junction’s protein in endothelial cells) was
significantly reduced in CBS+/- and CBS+/-/C3H mice as compared to WT and
C3H mice.
Western blotting for eNOS protein expression
We have observed eNOS down regulation in CBS+/- mice compared to WT mice
(Fig.10 A, B). Moreover, the protein expression of eNOS was up regulated in the
mesenteric artery of CBS+/-/C3H and C3H mice compared to CBS+/- mice.
HHcy facilitated collagen accumulation in the mesenteric artery
To observe collagen deposition in the mesenteric artery, Masson’s trichrome
staining was performed (Fig.11 A, B). Collagen content was significantly up
regulated in CBS+/- mice as compared to WT, C3H and CBS+/-/C3H mice. In
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addition, it was found that collagen accumulation was reduced in CBS+/-/C3H
mice as compared to CBS+/- mice.
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CBS+/- WT
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C3H

B.

CBS+/-
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7.

204 bp
108 bp
96 bp
Fig.3. Genotyping for CBS gene (A): CBS+/- and CBS+/-/C3H mice had two bands located at 450 and 308 bp while CBS+/+
mice had band located at 308 bp. PCR-RFLP for TLR-4 gene (B): TLR- 4 mutants (C3H and CBS+/-/C3H) had bands located
at 96 and 108 bp, whereas non-mutants (WT, CBS+/-) had a single band at 204 bp.
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Fig.4. A. Western blot for cystathionine β- synthase (CBS) protein expression, B. bar graphs for CBS
protein expression, normalized with GAPDH, * p<0.05 WT vs CBS+/-, # p<0.05 CBS+/- vs C3H,
WT vs CBS+/-/C3H, n=4.
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vs CBS+/-, # p<0.05 CBS+/- vs C3H,
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Fig.6. Mitochondrial dynamics in the mesenteric artery in HHcy: A. Western blot analysis of Mfn-2 and Drp-1 protein
expressions in WT, CBS+/-, C3H and CBS+/-/C3H mice mesentery. B. Bar graph for Mfn-2 and Drp-1 protein expressions in

mesentery, normalized with GAPDH, * p<0.05 WT vs CBS+/-, # p<0.05 CBS+/- vs C3H, n=4
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A.

B.

Fig.7. Alteration of mitochondrial dynamics in the mesenteric artery in HHcy: A. Real time expression of Mfn-2
mRNA in mesentery * p<0.05 WT vs CBS+/-, # p<0.05 CBS+/-vs C3H; B. Real time expression of Drp-1 mRNA in
mesentery * p<0.05 WT vs CBS+/-, # p<0.05 CBS+/- vs C3H, n=4

53

Fig.8. Mitochondrial fragmentation in HHcy: A. Mfn-2 and Drp-1 intensities in the mesenteric arteries of WT, CBS+/-,
C3H and CBS+/-/C3H. B. Bar graph for Drp-1 expression in the mesenteric artery * p<0.05 WT vs CBS+/-, # p<0.05 WT
vs CBS+/-C3H,

p<0.05 C3H vs CBS+/-/C3H; for Mfn-2 expression * p<0.05 CBS+/- vs C3H, n=4
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Fig.9. Immunohistochemistry of the mesenteric artery in different mouse groups: A. CD31 and Connexin 40
intensities in the mesenteric arteries of WT, CBS+/-, C3H and CBS+/-/C3H. B. Bar graph for respective proteins in
the mesenteric artery * p<0.05 WT vs CBS+/-, # p<0.05 CBS+/- vs C3H,
p<0.05 WT vs CBS+/-/C3H and C3H vs CBS+/-/C3H, n=4
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p<0.05 CBS+/- vs CBS+/-/C3H,

A.

B.

Fig.10. Western blot analysis of eNOS protein expression. A. Protein expression of eNOS in the
mesenteric arteries of WT, CBS+/-, C3H and CBS+/-/C3H mice. B. Bar plot for eNOS protein
expression normalized with GAPDH, * p<0.05 WT vs CBS+/-, # p<0.05 CBS+/- vs C3H,
CBS+/- vs CBS+/-/C3H, n=4
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p<0.05

Fig.11. Masson’s trichrome staining of the mesenteric artery in different mouse strains: A. Collagen intensity
in the mesenteric artery of WT, CBS+/-, C3H and CBS+/-/C3H mice, x20 magnification. B. Bar graph for collagen
expression in the mesenteric arteries * p<0.05 WT vs CBS+/-, # p<0.05 CBS+/- vs C3H, § p<0.05 CBS+/- vs CBS
+/-/C3H, n=4
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Discussion
Oxidative stress is the main outcome and major player in HHcy
pathogenesis. Many previous studies indicated the role of HHcy- mediated
oxidative stress in cardiovascular, cerebrovascular and renovascular diseases
[177-180]. In the present study we have observed the increase of Nox4
(oxidative stress marker), SOD- 1 (antioxidant marker) and SOD-2 (mitochondrial
antioxidant marker) in CBS+/- deficient mice as compared to WT, C3H and
CBS+/-/C3H mice (fig.2A, 2B). With these findings we assume that in
acute phase of oxidative stress in HHcy, the defensive mechanisms will be
activated trying to alleviate oxidative damage and balance the biological system.
However, in chronic stage of oxidative stress the defense mechanisms
will be exhausted and it would lead to antioxidant reduction that was confirmed
by previous reports [181]. In the meantime, studies have shown an increase of
SOD- 1 and SOD- 2 in oxidative stress [182] or HHcy [174, 183]. Interestingly,
SOD- 2 was also up regulated in C3H mice, suggesting that this mouse strain
has antioxidant properties and potentially more resistant to oxidative stress as
compared to other strains, however the precise mechanism is not defined until
now.
In the present study we have explored the effect of HHcy on mitochondrial
dynamics and the role of it in the development of mesenteric artery remodeling. It
has been reported that mitochondria constantly undergo fusion (regulated by
OPA-1, Mfn-1 and Mfn-2) and fission (regulated by Drp-1, Fis-1and MFF) in
response to physiological stimuli or stress. It has been shown that excessive
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mitochondrial fission and decreased mitochondrial fusion contributes to
mitochondrial fragmentation and accumulation of damaged mitochondria,
initiating mitophagy or cell apoptosis [22, 149, 184, 185]. Hyperhomocysteinemia
promotes intense mitochondrial fission and decreases mitochondrial fusion
facilitating cell death [23]. In the present study we have found a significant down
regulation of Mfn-2 (mitochondrial fusion marker) in CBS+/- deficient mice as
compared to WT and C3H mice. However, Drp-1 (mitochondrial fission marker)
was significantly up regulated in CBS+/- mice as compared to WT and C3H mice.
Interestingly, Mfn-2 was restored in CBS+/-/C3H mice as compared to CBS+/mice and Drp-1 protein expression was reduced in CBS+/-/C3H mice as
compared to CBS+/- mice.
The previous studies have reported that HHcy and oxidative stress
mediate endothelial cell layer damage that leads to endothelial nitric oxide
synthase loss and subsequent reduction in endothelium-dependent
vasorelaxation [169, 186, 187]. Our findings have showed eNOS down regulation
in CBS+/- mice as compared to WT, C3H and CBS+/-/C3H mice (fig.2C, 2D). In
addition, we have observed CD31 (endothelial cell marker) and connexin 40
reduction in CBS+/- mice as compared to WT, C3H and CBS+/-/C3H mice
(fig.6A, 6B). Connexin 40 is a gap junction protein that is highly expressed in the
endothelial cells. Previous reports confirmed that connexin 40 deficient
rodents develop arterial hypertension and exhibit impaired intercellular signaling
with altered propagation of vasodilation [175, 188, 189]. On the contrary, other
authors reported connexin 40 up regulation in endothelial cells during HHcy
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[190].
Previous study from our lab have shown that HHcy induces hypertension
and mesenteric artery remodeling through activation of MMP-9 followed by
collagen deposition [190]. The present study also showed collagen accumulation
in the mesenteric artery of CBS+/- mice as compared to WT, C3H and
CBS+/-/C3H mice (fig.7A, 7B).
In summary, these findings indicate the prevalence of mitochondrial fission
over mitochondrial fusion and oxidative stress in HHcy; which may explain
endothelial cell loss and dysfunction followed by collagen deposition that
contributes to mesenteric artery remodeling.
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CHAPTER V

TOLL- LIKE RECEPTOR 4 MUTATION SUPPRESSES
HYPERHOMOCYSTEINEMIA- INDUCED HYPERTENSION

Introduction

Primary or essential hypertension is the most common type of
hypertension with unclarified etiology that affects 95% of all hypertensive
patients. It has been reported that 75 million of adults in the United Sates and 1
billion people worldwide are affected by hypertension [191]. Persistent elevation
of blood pressure has been known to be a risk factor for the development of
stroke, myocardial infarction, chronic kidney and vascular diseases [192, 193]. A
high level of homocysteine (Hcy) or hyperhomocysteinemia (HHcy) is an
independent risk factor of hypertension [8, 194, 195]. Hcy is a product of
methionine metabolism that is cleared in the body by re-methylation and
transsulfuration pathways [1]. Hcy remethylation is mediated by methionine
synthase (MS), where vitamin B12 (cobalamin) is used as cofactor and 5methyltetrahydrofolate (5-MTHF) is utilized as the methyl donor [2]. 5-MTHF or
active form of folate (B9) is synthesized from 5, 10-methylenetetrahydrofolate by
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methylenetetrahydrofolate reductase (MTHFR). In transsulfuration, that occurs
only in the small intestine, liver, pancreas and kidney, a cofactor- vitamin B6
(pyridoxal phosphate) is required to convert Hcy to cystathionine by cystathionine
β- synthase (CBS) [3]. Cystathionine is hydrolyzed by vitamin B6- dependent
cystathionine gamma- lyase (CSE) to cysteine that is used as a precursor for
synthesis of antioxidant- glutathione or vasodilator-hydrogen sulfide [196].
Nutritional deficiencies in vitamin cofactors (B12, B9, and B6) and mutations in
MTHFR, CBS and CSE enzymes are the common causes of HHcy [197-200].
HHcy- mediated vascular dysfunction and remodeling, as the hallmarks of
hypertension, are developed due to complex of mechanisms, including instigation
of oxidative stress, mitochondrial apoptosis and inflammation. Hcy undergoes
auto-oxidation and has the ability to directly produce superoxide and hydrogen
peroxide due to highly reactive thiol group [201]. The presence of NO in oxidative
environment leads to peroxynitrite formation that further exacerbates oxidative
stress reducing NO bioavailability [202]. In addition, our group and other studies
have shown that in HHcy there is an increase in expression and activity of
NADPH oxidase that mediates superoxide production [171, 203]. Elevation in
Hcy level disrupts oxidant-antioxidant balance by diminishing the activity and
expression of the antioxidant enzyme glutathione peroxidase [204]. Apart from
oxidative stress, HHcy plays role in mitochondrial disorders instigation.
Mitochondrial dysfunction and mitochondria-dependent apoptosis have
been shown to promote endothelial cell loss leading to endothelial dysfunction
[15, 16] that contributes to pathogenesis of hypertension [17, 18]. The intrinsic
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pathway or mitochondria- dependent apoptosis [205, 206] is triggered by various
factors: ROS, DNA damage, Ca 2+ overload, hypoxia, oxLDL and is regulated by
B- cell lymphoma- 2 (BCL -2) family of proteins that are classified into proapoptotic (BAX) and anti-apoptotic proteins (BCL-2). BAX is expressed in cytosol
and is translocated to mitochondria upon activation where it initiates mitochondria
outer membrane permeabilization followed by cytochrome c release and
apoptosome (cytochrome c- APAF-1 complex) formation that plays role in
caspase- 9 and caspase- 3 activation. The effector caspase-3 facilitates DNA
and protein fragmentation that promote cell death. The third event mediated by
HHcy in addition to oxidative stress and mitochondrial dysfunction is vascular
inflammation.
Chronic vascular inflammation has been considered as one of the
mechanisms of the initiation and exacerbation of hypertension [74-76].
Inflammation is the immediate response of the immune system to the presence
of pathogens that is characterized by augmentation of pro- inflammatory cytokine
(IL- 1β, IL- 6, TNF- α) and chemokine (MCP-1) secretion that provide the
regulation of immune response and the migration of immune cells to target
organs. Several in vitro studies have shown inflammatory markers up-regulation
in HHcy, including activation of NF-kB that is inflammatory cytokine transcription
factor [10, 126]. Zhang et al. have reported that plasma IL-6, TNF-α and MCP-1
levels are positively correlated with Hcy levels[11]. Scherer et al. have also
observed mild HHcy- mediated augmentation of inflammatory cytokine
production (IL- 1β, IL- 6, TNF- α, MCP-1) in serum and different organs [12].
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Although HHcy is known to promote pro- inflammatory cytokine production, the
precise mechanism of inflammatory response initiation is still unclarified.
Pathogen recognition receptors, and in particular TLRs are the antigen sensors
that play role in innate immune system activation and have recently gained a
significant attention in the field of hypertension. There are 13 TLRs that have
been described in mammals (1-10 in humans and 11-13 in mice): cell surface
TLRs that sense the presence of bacteria and fungus (TLR- 1, 2, 4, 5) and TLRs
that localized to intracellular membranes and recognize viral or microbial nucleic
acid (TLR- 3, 7, 8, 9) [74]. The role of TLR- 4 that is ubiquitously present within
the vasculature (endothelial cells, VSMC) has been recently highlighted in sterile
inflammation. TLR-4 activation with downstream NF- kB- mediated cytokine upregulation has been implicated in pathogenesis of hypertension [13, 14]. Hence,
TLR-4 inhibition has been shown to reduce inflammatory cytokine elevation and
attenuate hypertension [87, 89]. Therefore, we hypothesize that HHcy induces
hypertension by TLR-4 activation that promotes inflammatory cytokine upregulation (IL-1β, IL-6, TNF-α) and initiation of mitochondria- dependent
apoptosis leading to cell death and chronic vascular inflammation. In addition, we
aimed to elucidate the role of TLR-4 mutation in attenuation of HHcy- mediated
vascular inflammation and mitochondria- dependent cell death.
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Materials and methods

Animal models
C57BL/6J (WT), cystathionine β- synthase deficient mice (CBS+/-) with
genetic mild HHcy, TLR- 4 mutants (C3H/HeJ) and mice with combined genetic
HHcy and TLR-4 mutation (CBS+/-/C3H) were used in the present study. The
age of the animals was 13- 14 weeks and the body weight was 25-30 g. The
mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). All
standard procedures and experiments with animals were followed in agreement
with the National Institute of Health and approved by Institutional Animal Care
and Use Committee (IACUC), University of Louisville.

Blood pressure measurement
BP was recorded using noninvasive tail cuff method (CODA; Kent
Scientific, Torrington, CT, USA). Prior to BP measurements the animals were
placed into the restraining chambers on a warm platform for 30 min for a 3
consecutive days to ensure mice adaptation to the procedure. BP was recorded
in a proper environment (room temperature, lightning and noise-free atmosphere)
for 4 mouse groups, 10 animals per each group were used (n=10).
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Vascular ultrasonography
Ultrasound of the superior mesenteric artery (SMA) was performed with
the Vevo 2100 system (Visual Sonics, Toronto, ON, Canada) under isoflurane
anesthesia. Physiological parameters (heart rate and respiratory rate) were
monitored during the procedure. The mouse was placed on a warmed platform
(370C) in supine position and the abdominal area was depilated. The imaging
was performed using acoustic gel (Other-Sonic, Pharmaceutical innovations,
Newark, NJ) that was applied on the skin in the abdominal area and a Vevo
MS550D transducer (13- 24 MHz). To calculate wall-to-lumen ratio, wall
thickness and lumen diameter were measured using SMA images in B mode.
The SMA resistive index (RI) was calculated as RI= (PSV- EDV)/ PSV, using
Peak systolic velocities (PSVs) and end- diastolic velocities (EDVs) measured in
pulsed- wave Doppler mode. The SMA pulsatility index (PI) was measured in
pulsed- wave Doppler mode and calculated as PI= (PSV- EDV)/ MV. Ultrasound
of the SMA was performed for 4 groups, 5 animals per each group were used
(n=5).

qPCR
To assess mRNA expression of different genes in the SMA, RNA was
isolated with TRIzol® reagent (Life Technologies, Carlsbad, CA, USA) according
to manufacturer's instructions. The RNA quantification and purity was assessed
by nanodrop-1000 (Thermo Scientific, Walthan, MA, USA). Aliquots (2μg) of total
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RNA were reverse- transcribed into cDNA using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) according to
manufacturer’s protocol. The q-PCR was performed for different genes (BAX, IL1β, IL- 6), in a final reaction volume of 20 ul containing 10 ul PerfeCTa SYBR
Green SuperMix, Low ROX (Quanta Biosciences, Gaithersburg, MD), 6 ul
nuclease free water, 2ul cDNA, 40 picomoles of forward, and reverse primers. All
sequence-specific oligonucleotide primers (Invitrogen, Carlsbad, CA, USA) are
presented in (Table 2). The data was represented in fold expression, calculated
as the cycle threshold difference between control and sample normalized with
housekeeping gene Rn18s.

Western blot analysis
The SMA protein content was extracted using mix of RIPA buffer (Boston
BioProducts, MA, USA), PMSF (Calbiochem, La Jolla, CA, USA) and protease
inhibitor (Sigma Aldrich, St. Louis, MO, USA). The protein extract was incubated
for overnight at 40C with shaking and centrifuged at 13 000 rpm for 20 min. The
supernatant was collected in another tube for protein estimation using Bradforddye method (Bio-Rad, CA, USA). The prepared protein lysate (60 ug) was heated
at 950C for 5 min and loaded on polyacrylamide gel with SDS in running buffer
and run at constant current (100 Volts). For protein transferring to PVDF
membrane electro transfer apparatus (Bio-Rad) was used. After transferring, the
membranes were blocked in 5% nonfat milk for 1 hour at room temperature,
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followed by overnight incubation with primary antibodies (Table 3) at 40C. After
washing with TBS-T buffer, membranes were incubated with secondary
antibodies for 1 hour at RT followed by washing step. The membranes were
developed with ECL Western blotting detection system (GE Healthcare,
Piscataway, NJ, USA) and all images were recorded in the gel documentation
system ChemiDoc XRS (Bio-Rad, Richmond, CA, USA). The membranes were
stripped with stripping buffer (Boston BioProducts, Ashland, MA, USA) followed
by blocking step with 5% milk for 1 hour at RT. After washing step membranes
were reprobed with anti- β- Actin antibody (Table 3) as a loading control protein.
The data were analyzed by Bio-Rad Image Lab densitometry software and
normalized to β- Actin bands.

Table 3
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Immunohistochemistry
The SMA tissue was immersed in tissue- freezing medium (Triangle
Biomedical Sciences, Durham, NC, USA) in disposable plastic tissue- embedding
mold (Polysciences Inc., Warrington, PA, USA). The tissue blocks were kept at 800C until use. To obtain 5 um thickness sections Cryocut (CM 1850; Leica
Microsystems, Buffalo Grove, IL, USA) was used. Tissue sections were placed
on polylysine coated slides (Polysciences, Inc., Warrington, PA, USA). Tissue
sections were incubated with permeabilization solution (0.2 g Bovine Serum
Albumin, 3 ul Triton X-100 in 10ml 1X PBS) for 1 hour at RT followed by washing
step with 1X PBS. The sections were incubated with primary antibody (Table 3)
with 1: 250 dilution for overnight at 40C. After washing with 1X PBS the slides
were incubated with fluorescently labeled secondary antibodies (gout anti-mouse
Alexa flour 488 and gout anti-rabbit Texas red; Invitrogen, Waltham, MA, USA)
with 1: 500 dilution for 1 hour at RT followed by DAPI staining with 1: 10,000
dilution for 20 min at RT. After washing step the slides were mounted with
mounting medium and visualized using laser scanning confocal microscope
(Olympus Fluo View 1000; Center Valley, PA, USA). The images were analyzed
by measuring fluorescence intensity with Image Pro-Plus software (Media
Cybernetics, Rockville, MD, USA).
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TUNEL assay
The DeadEnd Fluorometric TUNEL system measures nuclear DNA
fragmentation that is an important biochemical hallmark of apoptosis. TUNEL
System detects fragmented DNA by catalytically binding fluorescein-12-dUTP to
3’-OH DNA ends using Terminal Deoxynucleotidyl Transferase, Recombinant,
enzyme (rTdT). The TUNEL assay was performed on frozen SMA tissue sections
using commercially available kit (DeadEnd Fluorometric TUNEL System,
Promega, Madison, WI, USA). The assay was done according to manufacturer’s
protocol for tissue staining including positive control preparation and nuclear
staining with DAPI. The slides were visualized with confocal microscope
(Olympus Fluo View 1000; Center Valley, PA, USA) using green fluorescent filter
to detect DNA fragmentation and blue DAPI filter for nucleus detection. The
images were analyzed with Image Pro-Plus software (Media Cybernetics,
Rockville, MD, USA).

Statistical analysis
Statistical analysis was performed with Primer of Biostatistics 7.0
(McGraw-Hill, NY, USA). To determine the significance, we used one-way
analysis of variance (ANOVA) followed by multiple comparison test (Holm test)
between the groups. The difference was considered significant when p< 0.05.
Values are presented as mean ± SEM (n≥ 4).
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Results
TLR- 4 mutation suppresses HHcy- mediated hypertension
Hyperhomocysteinemic mice (CBS+/-) had significantly higher systolic,
diastolic and mean BP than in the WT mice (Fig.12). TLR- 4 mutated mice (C3H)
had significantly lower systolic, diastolic and mean BP compared to WT group
(Fig.12). Mouse group with combined genetic HHcy and TLR- 4 mutation (CBS+//C3H) had significantly lower systolic, diastolic and mean BP than in the CBS+/group (Fig.12).
Wall-to-lumen ratio, RI and PI
To assess the structural changes in the SMA the wall thickness and the
lumen diameter were measured and the SMA wall-to-lumen ratio was calculated
accordingly. It was found that the SMA wall-to-lumen ratio was increased in the
CBS+/- mice compared to WT and C3H groups (Fig. 13 A, B). The SMA wall-tolumen ratio of the CBS+/-/C3H mice was similar to the control group (Fig. 13 A,
B). The resistive index (RI) and pulsatility index (PI) were calculated from the
blood flow velocities in the artery during cardiac cycle and were used to
determine a peripheral resistance. The RI and PI of the SMA were increased in
CBS+/- mice compared to WT and C3H groups (Fig.14 A, B). The SMA RI and PI
were similar to the control in the mouse group with combined genetic HHcy and
TLR-4 mutation (Fig.14 A, B).
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TLR-4 mutation reduces vascular inflammation
To examine inflammatory marker activation we analyzed TLR-4 and TNFα expression by IHC (Fig.15 A, B); IL-1β, IL- 6 mRNA expression by q- PCR
(Fig.16 A, B). IHC showed increased intensity of TLR-4 and TNF- α in the SMA of
CBS+/- mouse group. TLR-4 and TNF- α intensities were reduced in mouse
group with combined genetic HHcy and TLR-4 mutation. IL-1β, IL- 6 mRNA
expression was elevated in the SMA of CBS+/- mouse group and reduced in the
SMA of CBS+/-/C3H mice.
TLR- 4 mutation attenuates mitochondria- mediated cell death
To evaluate apoptotic marker activation we analyzed BAX gene
expression by q- PCR (Fig.17), caspase- 9 protein expression by western blotting
(Fig.18) and cleaved caspase- 3 expression by IHC (Fig.19). BAX mRNA
expression was significantly up regulated in CBS+/- mice compared to other
groups. CBS deficient mice with TLR- 4 mutation (CBS+/-/C3H) had reduced
BAX mRNA expression compared to CBS+/- mice. Caspase- 9 protein
expression was significantly increased in HHcy mice (CBS+/-) and in CBS+//C3H group than in the WT and TLR-4 mutated (C3H) mice. In addition, the up
regulation of cleaved caspase- 3 expression in CBS+/- mice was confirmed by
IHC. The intensity of cleaved caspase- 3 was reduced in the SMA of CBS+/-/C3H
mice compared to CBS+/- group. These results suggest the induction of
mitochondria- dependent apoptosis in HHcy and that TLR- 4 mutation mitigates
mitochondria-mediated apoptosis.
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TLR- 4 mutation mitigates HHcy- induced DNA fragmentation
TUNEL assay was used to evaluate DNA fragmentation in the SMA of
different groups (Fig. 20). DNA fragmentation was significantly augmented in the
SMA of CBS+/- mice compared to WT and C3H mice. TUNEL positive cell count
was reduced in the SMA of CBS+/-/C3H mice as compared to CBS+/- group.
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Fig. 12. Systolic, Mean and Diastolic blood pressure (BP) : HHcy mice had significantly higher systolic, mean and
diastolic BP and mouse group with combined genetic HHcy and TLR- 4 mutation (CBS+/-/C3H) had significantly
lower systolic, mean and diastolic BP. n=10; *p< 0.05 WT vs CBS+/-; # p< 0.05 WT vs C3H;
CBS+/-/C3H.
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p< 0.05 CBS+/- vs

A.
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C3H

SMA wall-to-lumen ratio

WT

CBS+/-/C3H
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Fig. 13. Wall-to-lumen ratio A.: to assess the structural changes in the SMA, the wall thickness and the lumen diameter

were measured and the SMA wall-to-lumen ratio was calculated accordingly. B. bar graph for wall-to-lumen ration values
in different groups. It was found that the SMA wall-to-lumen ratio was increased in the CBS+/- mice compared to WT and
C3H groups. The SMA wall-to-lumen ratio of the CBS+/-/C3H mice was similar to the control group ; n=5; *p< 0.05 WT vs
CBS+/- ; # p< 0.05 CBS+/- vs CBS+/-/C3H.
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Fig.14. PI, RI of the SMA A: The pulsatility index (PI) and the resistive index (RI) are calculated from the blood flow velocities in
the artery during cardiac cycle and are used to determine a peripheral resistance. B. bar graph for RI and PI values in different
groups. The PI and RI of the SMA were increased in CBS+/- mice compared to WT and C3H groups. The SMA PI and RI were
similar to the control in the mouse group with combined genetic HHcy and TLR-4 mutation; n=5; *p< 0.05 WT vs CBS+/- ; # p<
0.05 CBS+/- vs CBS+/-/C3H
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Fig.15. Immunohistochemistry for TLR-4 and TNF- α (A, B): IHC showed increased intensity of TLR-4 and TNF- α in
the SMA of CBS+/- mouse group. TLR-4 and TNF- α intensities were reduced in mouse group with combined genetic
HHcy and TLR-4 mutation, n=4; *p< 0.05 WT vs CBS+/- ; # p< 0.05 CBS+/- vs CBS+/-/C3H
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Fig.16. Quantitative RT-PCR for IL-1β gene (A) and IL-6 gene (B): IL-1β, IL- 6 mRNA expression was elevated in the SMA of
CBS+/- mouse group and reduced in the SMA of CBS+/-/C3H mice ; (A): n=5; *p< 0.05 WT vs CBS+/- ; # p< 0.05 CBS+/- vs
CBS+/-/C3H; (B): n=4; *p< 0.05 WT vs CBS+/- ; # p< 0.05 CBS+/- vs C3H, p< 0.05 CBS+/- vs CBS+/-/C3H
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Fig.17. Quantitative RT-PCR for BAX gene: BAX mRNA expression was significantly up regulated in
CBS+/- mice compared to other groups. CBS deficient mice with TLR- 4 mutation (CBS+/-/C3H) had
reduced BAX mRNA expression compared to CBS+/- mice n=4; *p< 0.05 WT vs CBS+/- ; # p< 0.05
CBS+/- vs CBS+/-/C3H
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Fig.18. TLR- 4 mutation attenuates mitochondria- mediated cell death: Caspase- 9 protein expression was increased in HHcy
mice (CBS+/-) and in CBS+/-/C3H mouse group compared to WT and TLR-4 mutated (C3H) mice; n=6; *p< 0.05 CBS+/- vs C3H;
# p< 0.05 C3H vs CBS+/-/C3H

80

C.

DAPI

Caspase-3

Merged

WT

CBS+/-

Cleaved caspase-3
intensity

26

C3H

CBS+/-/C3H

*
#
13

0

WT

CBS+/-

C3H

CBS+/-C3H

Fig.19. Immunohistochemistry for cleaved caspase-3: IHC showed elevated levels of cleaved caspase-3 in SMA of CBS+/- mice.
The intensity of cleaved caspase-3 was reduced in the SMA of CBS+/-/C3H mice compared to CBS+/- group; n=4;
*p< 0.05 WT vs CBS+/- ; # p< 0.05 CBS+/- vs CBS+/-/C3H
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Fig.20. TLR- 4 mutation mitigates HHcy- induced DNA fragmentation: TUNEL assay were used to evaluate DNA
fragmentation (indicated with arrows) in the SMA of different groups (A, B). DNA fragmentation was significantly augmented in
the SMA of CBS+/- mice compared to WT and C3H mice. TUNEL positive cell count was reduced in the SMA of CBS+/-/C3H
mice as compared to CBS+/- group, n=4.
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Discussion

Elevated plasma Hcy has been shown to be a risk factor for the peripheral
arterial disease and hypertension [8, 197, 207, 208]. In our previous work we
have shown that HHcy induced endothelial cell injury and peripheral vascular
remodeling with collagen deposition in the SMA [203]. Consistent with our
findings, several studies reported that HHcy promotes endothelial cell injury,
vascular endothelial dysfunction and vascular remodeling that contribute to
pathogenesis of hypertension [209-211]. The elevation of total peripheral
resistance that is attributed to alterations in structural and physical properties of
the resistance arteries is the hallmark of primary or essential hypertension. In the
present study, using ultrasonography, the increased SMA wall-to-lumen ratio, RI
and PI were detected in CBS+/- mice that is an indication of inward vascular
remodeling and peripheral resistance elevation due to HHcy. The increase in
peripheral vascular resistance has been associated with raised systolic, diastolic
and mean arterial blood pressure values in CBS+/- mouse group. The RI, PI and
wall-to-lumen ratio of the SMA in mouse group with combined genetic HHcy and
TLR-4 mutation (CBS+/-/C3H) were similar to the control group that could explain
attenuation of HHcy- mediated high blood pressure.
A significant number of studies have described inflammation as one of the
toxic effects of Hcy. Zhang et al. reported that plasma Hcy was positively
correlated with plasma pro-inflammatory cytokine and chemokine (IL-6, TNF- α
and MCP-1) levels and promoted inflammatory monocyte differentiation [11].
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Zanin et al. have shown that HHcy is involved in the synthesis and secretion of
IL-1β via NF- kB in murine macrophages [124]. Han et al. have observed
endothelial cell inflammatory injury through activation of NF-kB and cytokine IL-6
up regulation in HHcy [125]. In agreement with previous findings, we have found
an up-regulation of pro- inflammatory cytokine expression (IL-1β, IL- 6 and
TNF- α) in the SMA of CBS+/- mouse group that confirmed chronic vascular
Inflammation induced by genetic mild HHcy. In addition, we observed that
mice with combined genetic HHcy and TLR-4 mutation have less proinflammatory cytokine (IL-1β, IL- 6 and TNF- α) expression in the SMA compared
to CBS+/- mouse group, indicating that TLR-4 mutation prevents HHcy-induced
chronic vascular inflammation. The role of TLR-4- mediated signaling pathway
has been recently highlighted in pathophysiology of several CVDs including
hypertension [212-215]. Pryshchep et al. have observed the abundant
expression of TLR-4 in all cell types of 6 different vascular beds (aorta, carotid,
temporal, subclavian, iliac and mesenteric arteries). It was confirmed that TLR-4
is expressed in EC and VSMC in atherosclerosis while in normal, non-inflamed
arteries adventitial DC are the major sensors of pathogen-related motifs [216].
McCarthy et al. have described the role of musculoskeletal injury- induced
endothelial TLR-4 and damage-associated molecular pattern molecules
(DAMPs: HMGB1, mtDNA) interaction in the development of hypertension in
football players [13]. Dange et al. reported increased blood and brain TLR-4,
TNF-α and IL-1β expressions in Angiotensin II- induced hypertension
and have also shown that central blockade of TLR-4 delayed the progression of
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hypertension and improved cardiac function in hypertensive rats [217]. Bobek et
al. have observed that TNF-α- infused mice developed proteinuric hypertension
similar to human preeclampsia that was accompanied by TLR-4 protein
expression up-regulation in placenta [218]. Li et al. have reported TLR-4- induced
MMP-9 elevation in human aortic smooth muscle cells and confirmed that TLR-4
siRNA silencing regulated the MMP-9 expression, indicating the role of TLR-4mediated signaling pathway in vascular remodeling [219]. Balistreli et al. for the
first time described rs4986790 TLR-4 polymorphism that confers a higher
susceptibility for sporadic thoracic aorta aneurism (TAA) and together with
rs1799752 ACE, rs3918242 MMP-9, and rs2285053 MMP-2 SNPs is an
independent sporadic TAA risk factor. In addition, the authors observed that the
cases with combined risk genotype showed higher levels of inflammatory
mediators and plasma MMP-9, MMP-2 levels that was accompanied by elastic
fragmentation in tissue aorta samples [220, 221]. In previous work we have
reported TLR-4, IL-1β, IL-6 and TNF- α up-regulation in heart tissues of CBS+/
mice with genetic mild HHcy. The inflammatory markers were further increased
when mice were fed with high methionine diet that exacerbated HHcy [222]. In
agreement with previous studies, we have found TLR-4 expression up- regulation
in the SMA of CBS+/- mice that connects the downstream inflammatory cytokine
signaling pathway activation in mild HHcy. The mouse group with combined
genetic HHcy and TLR-4 mutation exhibits less TLR-4 expression compared to
CBS+/- mouse group preventing downstream inflammatory cytokine elevation.
Mitochondria- dependent apoptosis has been implicated in the induction of
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vascular remodeling that contributes to pathogenesis of hypertension [223-225].
A significant number of studies have described the role of HHcy in the initiation of
mitochondria- dependent apoptosis through activation of ROS. Kim et al. have
shown that Hcy treatment of primary human bone marrow stromal cells led to
activation of ROS, caspase-9, 3 and cytochrome c release into the cytosol from
mitochondria, suggesting that mitochondria- initiated cell death pathway is a
predominant mechanism of apoptosis in HHcy [226]. Sipkens et al. have
observed elevation of cellular NOX2, NOX4 and Hcy treatment concentration
dependent increase of caspase- 3 in human umbilical vein endothelial cells [227].
Moreira et al. reported that Hcy increases superoxide levels and cell death
in human aortic endothelial cells, but vitamin B12 supplementation prevents
oxidative stress- induced cellular death [228]. However, there are studies that
have been stressing on inflammatory component as the critical mechanism of
mitochondria-mediated cell death. Pan et al. reported that NF-kB is a
transcription factor that regulates the expression of both pro-inflammatory genes
and genes that contribute to mitochondria-dependent apoptosis (BCL-2 gene
family) [229]. It has been implicated that NF-kB activation happens prior to DNA
fragmentation and is accompanied by up-regulation of pro-apoptotic proteins
(BAX) [230, 231]. Aoki et al. have reported that NF-kB promotes endothelial cell
death through translocation of BAX to mitochondria and down- regulation of Bcl-2
[232]. In the present study, we have found an up-regulation of BAX, caspase-9,
caspase-3 expression in the SMA of CBS+/- mice with mild HHcy compared to
control group. The mouse group with TLR-4 mutation alone expressed less BAX,
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caspase-9, caspase-3 in the SMA tissue. The group with combined genetic HHcy
and TLR-4 mutation exhibited down regulation of BAX, caspae-3 expression in
the SMA. In addition, DNA fragmentation in the SMA was increased in the mouse
model of mild HHcy, but groups with TLR-4 mutation (C3H, CBS+/-/C3H) showed
decreased DNA fragmentation in the SMA tissue. These findings suggest that
TLR-4- driven inflammatory signaling pathway contributes to initiation of
mitochondria- mediated cell death and TLR-4 mutation prevents the onset of
mitochondrial apoptosis.
To summarize, our study for the first time has illustrated that Hcy acts
through TLR-4 receptors that are highly expressed in all cell types of the vascular
bed HHcy- mediated TLR-4 activation promotes chronic vascular inflammation
with pro- inflammatory cytokine elevation, facilitating mitochondria- mediated cell
death that all favor inward vascular remodeling. In our work we have also
demonstrated that TLR-4 mutation attenuated chronic vascular inflammation and
mitochondria- induced cell injury that prevented peripheral vascular remodeling
and suppressed hypertension.
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CHAPTER VI

SUMMARY, CONCLUSION AND FUTURE DIRECTIONS

Experimental studies have demonstrated that elevated plasma Hcy is a
risk factor for the peripheral arterial disease and hypertension. However, the
precise mechanism of detrimental Hcy interaction with vascular wall is
incompletely understood. In the present study we have described different
aspects of Hcy action in the development of peripheral vascular remodeling that
is a hallmark of hypertension. Our study for the first time has illustrated that Hcy
acts through TLR-4 receptors that are highly expressed in all cell types of the
vascular bed. HHcy-mediated TLR-4 activation promotes chronic vascular
inflammation with pro-inflammatory cytokine elevation, facilitating mitochondriamediated cell death that all favor inward vascular remodeling. In our work we
have also demonstrated that TLR-4 mutation attenuated chronic vascular
inflammation and mitochondria-induced cell injury that prevented peripheral
vascular remodeling and suppressed hypertension.
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Future Directions:
Several experimental studies have illustrated the promising effect of TLR4-targeted therapy in prevention of hypertension. However, further studies are
required for detailed investigation of the role of TLR-4-mediated signaling
pathway in pathogenesis of hypertension and other CVDs. Future studies that
will elucidate the mechanisms that underlie TLR-4-mediated inflammatory
pathway may offer novel concepts for hypertension therapy.
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